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British Oncological Association Lecture
Small cell lung cancer: new discoveries and future directions
R.L. Souhami
Department ofOncology, University College and Middlesex
School ofMedicine, Middlesex Hospital, London WIP 7PN,
UK.
A recent UK survey has shown that with current treatments
only 2.6% of patients with small cell lung cancer (SCLC) will
survive 6 years. Death from SCLC does not occur after this
time. This result indicates both that cure is possible and that
new approaches to treatment will be necessary. For patients in
the most favourable prognostic categories more intensive
chemotherapy regimens (which are already capable ofproduc-
ingcomplete response rates ofup to 50%) mayimprove results.
Intensive treatments using autologous bone marrow transplan-
tation have, so far, been disappointing. Weekly intensive
regimens can be given safely and give very high response rates.
Even when chemoresistant, SCLC remains radiosensitive.
Systemic radiation may be a useful means of consolidating
treatment in patients responding completely to chemotherapy.
As a result of international collaboration, membrane antigens
have been defined on SCLC which are potential candidates for
radiolabelled antibody targeting. The most immunodominant
has been designated cluster 1 and is now known to be the neural
cell adhesion molecule N-CAM.
The growth of SCLC can also be slowed by blocking the
autocrine growth stimulatory effect ofgastric-releasing peptide
(GRP). GRP is one of a family of molecules which bind to
SCLC surface membrane and whose actions may be inter-
rupted by antagonists binding to specific receptors.
Conference Lecture
Biological and clinical implications of physical dose
optimisation in radiotherapy
H. Bartelink
The Netherlands Cancer Institute, Amsterdam, The
Netherlands
Recent developments in radiotherapy, such as multileaf col-
limators, three-dimensional treatment planning systems or high
energy electron irradiation, have led to a new era in
radiotherapy. These developments allow administration of
higher doses at primary tumour sites with equal or even lower
radiation doses in the surrounding normal tissues. It is hoped
that these efforts of improving the treatment procedure will
lead to an increase in cure rate. New forms of therapy,
however, always carry with them the risk of serious complica-
tions. A large increase ofthecomplication rate can occurdue to
small errors as the dose-effect curves for normal tissue compli-
cations are much steeper than those for tumour. New methods
for patients' daily set-up and control procedures have to be
introduced in the clinic to ensure that the intended more precise
radiation therapy is carried out according to treatment plan.
For selection ofthe optimal treatment plan new criteria have to
be developed to estimate the gain and the risk of new ways of
treatments. These selection criteria for choosing the optimal
treatment plan should be based upon alpha/beta values for
tumours and normal tissues in humans. Even proliferation
rates of normal tissues and tumours have to be known and
should be measured in order to design new treatment regimens.
Prospective studies and prospective clinical trials with different
radiation doses have to be carried out to estimate the alpha/
beta values. For the proliferation rate the IUDR method is a
novel approach to measure the potential doubling time. An
almost complete uncertainty exists on the influence of irradia-
tion volume on the organ tolerance. Ongoing studies on
tolerance of lung and small bowel in relation to dose and
volume will provide data on normal tissue toxicity. These data
on normal tissue tolerance with regard to dose fractionation
schedule and volume effect have to be incorporated in treat-
ment planning systems to provide a reasonable estimate ofthe
risk benefit ratio of new methods of treatment. The results of
physical dose optimisations are to a large extent dependent on
the quality control of the radiation procedure. Introduction of
on-line methods such as the megavoltage imaging device and in
vivo dosimetry are assayed to control the whole treatment
procedure. Only in this way will the anticipated gain ofthe dose
optimisation be realised.
Louise Buchanan Memorial Lecture
Tumour cell differentiation: an important concept in clinical
oncology
N.A. Wright
Department ofHistopathology, Royal Postgraduate Medical
School and Imperial Cancer Research Foundation Labs,
London, UK.
In recent years, the aspect of the malignant phenotype which
has received most attention is growth and proliferation; the
differentiation of tumour cells has, until recently, been
relatively neglected.
Differentiation in malignancy can be approached on several
different levels. As its simplest level, the behaviour ofa tumour
can often be predicted by its differentiation pattern; an example
is that tubule formation in carcinoma of the colon is an
independent variable in predicting metastatic behaviour. But
now the factors which determine tubule formation in car-
cinoma of the colon are becoming recognised at the cell
biological and molecular genetic level.
The malignant change itself can be regarded as a defect in
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differentiation: carcinomas contain terminally differentiated
cells, and indeed these can be induced by modulating the
growth conditions.
Both these considerations point to the conclusion that the
malignant phenotype is not immutable, even in solid tumours,
and that further understanding of the biological basis of
differentiation in normal and malignant cell populations might
suggest novel therapeutic procedures formodulating themalig-
nant phenotype.
Conference Lecture
Early detection of prostate cancer: is it necessary, is it
possible?
P. Scardino
Professor of Urology, Baylor College ofMedicine, Houston,
Texas, USA.
The prostate has become the leading site ofcancer in men and
prostate cancer is the second leading cause of death from
cancer in men in the USA. The prevalence of prostate cancer
found at autopsy in men suggests that adenocarcinoma of the
prostate is the most common malignancy in human beings.
Traditionally theearly detection ofprostate cancer in asympto-
matic men has depended upon digital rectal examination
(DRE). Recently, two new techniques capable of detecting
prostate cancer in men with a normal digital rectal examination
have become available: measurement of prostate specific
antigen (PSA) and transrectal ultrasonography (TRUS). Yet
the prospect ofusing these techniques in widespread screening
or early detection programmes has generated considerable
controversy. Both the efficacy of these techniques and the
necessity for early detection of this slow-growing cancer have
been seriously questioned. Because of the remarkably high
prevalence of cancer in the prostate found at autopsy of men
who die of other causes, the slow progression rate of the
tumour, and the advanced age of men diagnosed with the
disease, patients with prostate cancer are often said to be more
likely to die with rather than oftheirdisease. On the otherhand,
once prostate cancer is diagnosed - whether by digital rectal
examination, the pathological examination of the tissue from
transurethral resection ofthe prostate (TURP), or the develop-
ment ofsymptoms - treatment has been generally unsuccessful
in controlling the disease except in its very early stages. With
28,500 men dying ofthe disease in the USA this year, the need
for earlier detection seems evident.
This paper will review: (1) the results of treatment trials for
early stage prostate cancer; (2) the natural history of the
disease; and (3) the features of'clinical' and 'autopsy' prostate
cancer, all of which together provide a rational basis for the
early detection that is essential if the mortality rate from
prostate cancer is to decline.
Bob Champion Cancer Trust Lecture
Dose effect with bone marrow transplantation in lymphomas
and solid tumour
T. Philip
Centre Leon Berard, Bone Marrow Transplant Department,
Lyon Cedex 08, France.
Autologous bone marrow transplantation is a tool to increase
the dose-effect relationship in cancer therapy. In lymphomas,
BMT is able to cure 70-75% of patients in partial response
after induction therapy and 40% of patients still sensitive to
rescue protocols at time ofrelapses. Primary refractory patients
and resistant relapse patients are not curable yet. Addition of
interleukin-2 post BMT could be a discussion to improve
results for these patients.
In solid tumours encouraging results have been reported for
neuroblastoma in children and testicular cancer in adults.
However, ABMT is still an experimental procedure in this field
and future directions will be reviewed.
Oral presentations
New approaches in oncology
Neutron therapy for squamous cell carcinoma of the head and
neck: the 5-year follow-up ofthe Edinburgh randomised
clinical trial
R.H. MacDougall, J.A. Orr & G.R. Kerr
Department ofClinical Oncology, University ofEdinburgh,
UK.
One hundred and sixty-eight patients were recruited into a
randomised trial ofd(l5) + Be fast neutron therapy compared
with 4MV photons in the treatment of locally advanced
squamous cell carcinoma ofthe head and neck. Results with a
minimum of two years' follow up were reported in 1987
(Duncan et al. (1987), Int. J. Radiat. Oncol. Biol. Phys., 13,
171).
In May 1989 five-year follow-up became available for all
patients. The five-year survival rate for neutrons is 23.5% and
for photons 33.8% (P = 0.085). The disease-free survival for
neutrons is 18.8% and for photons 30%.
Late grade 4/5 morbidity associated with neutrons exceeded
that of photons.158 BRITISH ONCOLOGICAL SOCIETY MEETING
Excision, interstitial "1Ir and myocutaneous flap repair for the
salvage of patients with head and neck cancer developing fixed
nodal recurrence in the irradiated and dissected neck
M.H. Robinson, J.M. Henk, N. Stafford & P. Rhys Evans
Head and Neck Unit, Royal Marsden Hospital, London, UK.
Relapse of head an neck cancer with a fixed node mass
following a neck dissection and radical radiotherapy is
associated with a very poorprognosis. Where complete surgical
clearance is unattainable these patients have been regarded as
unsalvageable. We report the results of treatment of 27 such
patients, median age 61.5 years. In an effort to improve these
results 17/27 patients were treated with a combination of
surgical resection, interstitial '92ir implant and repair of the
defect by a myocutaneous flap. Six had been treated by surgery
and implant without resurfacing, and four with implant alone.
Seven patients had a laryngeal primary, six oral cavity, two
oropharyngeal, two hypopharyngeal and 10 other sites. The
median interval between initial irradiation and the implant was
16 months and median total dose received by the 27 patients
was 102.8 Gy (range 89-128 Gy). Five of six patients treated
without resurfacing developed soft tissue necrosis, most healing
spontaneously. The median implant dose used was 43.4 Gy
(range 30-60 Gy) but since no complications have developed
where a myocutaneous flap was used an implant dose of 50 Gy
is now routine. The four patients not having surgery had
persistent disease after treatment: one whose tumour was only
debulked relapsed at the implant site and in the other neck. Of
the remaining patients seven remained disease-free, four
developed metastatses, two relapsed at the implant site alone,
six outside the implant site and one at both sites. The median
survival and disease free period of those having surgery are
11.25 months and 10.7 months respectively. The use of a
myocutaneous flap and 192Ir afterloading following excision is a
potentially valuable method of treating these difficult prob-
lems.
Hydralazine increases blood flow through humanlung tumours
N.P. Rowell, B. Cronin, V.R. McCready &A. Horwich
The RoyalMarsden Hospital, Sutton andMRCRadiobiology
Unit, Harwell, UK.
Hydralazine has been shown both to reduce tumour blood flow
and to potentiate the cytotoxicity of melphalan and the
bifunctional nitroimidazole RSU 1069 in mice. In order to
determine whether such a strategy has clinical potential, the
effects of hydralazine on blood flow through human tumours
were investigated in fifteen patients with carcinoma of the
bronchus (mean age 67; range 52-75 years) who received a
single oral dose ofhydralazine in the range 0.37-2.26 mg kg-'
according to age, acetylator status and an escalating dose
schedule. Tumour blood flow was assessed by single photon
emission computed tomography (SPECT) performed ten
minutes following intravenous 99Tcm-HMPAO on two
occasions 4-8 days apart, the second being performed 60 min
after hydralazine. Blood pressure and cardiac output were
measured non-invasively and repeatedly throughout.
Hydralazine caused a 25% increase in tumour blood flow
(P = 0.065), with a trend for greater increases to occur in
patients sustaining greater falls in peripheral resistance.
Tumour vascular resistance (calculated from blood pressure
and estimates ofblood flow) fell, indicating active vasodilation
in arterioles supplying tumours. Common symptoms in higher
doses were giddiness, palpitations and facial flushing. Doses
greater than 1.5-2.0 mgkg-' were poorly tolerated. Allowing
for extensive first-pass metabolism in the liver, these doses are
equivalent to only a fraction of those used in animal studies.
High dose melphalanimprovestheprognosisin advanced
neuroblastoma: resultsofa randomisedstudy of'ENSG- 1'
J. Pritchard, S. Germond, D.H. Jones&J. de Kraker
European Neuroblastoma Study Group.
We wished to investigate the value of high dose melphalan
(HDM) as 'consolidation therapy' in children with advanced
neuroblastoma. One hundred and thirty patients over 6 months
of age with Evans stage III or IV tumours, consecutively
referred to 16centres, were given 3-4weekly 'OPEC' induction
therapy and, where possible, had the primary tumour resected.
Ninety patients (69.2%) achieved complete response or good
partial response (disappearance of all evidence of secondary
deposits and shrinkage of primary by > 50% in each of three
dimensions), and were eligible, after stratification by stage and
centre, for randomisation either to one high dose ofmelphalan
(180mgm2) with autologous bone marrow rescue or to no
further treatment. Because ofnon-compliance by some parents
and physicians only 65 patients were actually randomised.
Despite serious toxicity including two treatment-related deaths,
patients in the HDM group had better event-free survival
(median 24 vs 8 months; 2-sided P = 0.045, log rank) than
those in the 'no further treatment' group. Results were similar
for children with the worst prognostic features, i.e. those with
stage IV disease aged over 12 months at diagnosis (disease-free
survival median 22 vs 5 months; two-sided P = 0.025, log
rank). Though longer follow-up is needed to establish the
pattern of long-term survival we conclude that HDM is of
benefit to children with advanced neuroblastoma who have
achieved complete or good partial response after OPEC and
surgery.
A preliminary reportoftreatment for in-transit metastatic
melanomawith acarbondioxide laser
J.M. Gattuso, R. Waters& J. Meirion Thomas
Westminster Hospital, London, UK.
Six patients (aged 60-79 years) with a total of 116 lesions on
the legs were treated with a carbon dioxide laser. Three patients
had recurrent disease following isolated limb perfusion and the
other three were treated by laser in preference to isolated limb
perfusion. Two patients were treated for the second time for
new lesions. General anaesthetic was used initially as the level
of anaesthetic required was unknown. Subsequently two
treatments were done under local anaesthetic. Operating time
varied with the size and number of the lesions treated. For
example, in case 1, 40 lesions, 1.5-16 mm diameter, were
treated in 30 min. Postoperative pain in all cases was absent or
minimal, and if present was always relieved by simple oral
analgesics. Wounds were not sutured and within 24-48 h adry
eschar developed. Therefore only simple dry dressings were
necessary and minimal nursing care was required. No patient
developed infection, cellulitis or needed antibiotics. Patients
could be discharged home the next day and in future day-case
treatment will be considered suitable. Patient follow-up is still
continuing, however it does appear that the laser treatment is
locally curative. Further recurrences have always occurred at
new sites. Inconclusion, laser treatment has several advantages
over conventional treatment. It offers rapid and effective
treatment for multiple recurrences, it can be used in the
outpatient clinic under local anaesthetic and minimal post-
operative care is required. In selected patients the technique is
likely to complement or replace isolated limb perfusion.BRITISH ONCOLOGICAL SOCIETY MEETING 159
Decision making in oncology
Early gastric cancerdetection: an achievable aim
M.T. Hallissey, A. Jewkes, J.W.L., Fielding, D.J. Ellis &
W.H. Allum
Department ofSurgery, Queen Elizabeth Hospital, Birmingham,
UK.
The Japanese have demonstrated that the detection of early
and curable gastric cancer is an achievable aim. Despite the
advances in the diagnostic tools avilable, the West has seen
little change in the proportion of operable cases in the past 30
years. While mass radiographic screening is impractical in the
UK, the identification of a high risk group may allow a suitable
programme of early detection to be developed. Dyspeptic
patients over the age of 40 form such a group, in whom early
investigation may increase the detection of curable gastric
cancer.
A study was established with six general practices in central
Birmingham in 1984 and a further four in Sandwell in 1986.
The aim was to provide an endoscopic diagnosis in all dyspep-
tic patients aged over 40 within 3 weeks of attending surgery.
To the end of 1988, 2,703 patients have been entered ofwhom
77% had identifiable pathology. There were 107 malignancies
diagnosed of which 53 were gastric carcinomas. Of the gastric
cancers, 21.4% were stage I, 12.5% stage II and 28.6% stage
III. Over the first 2 years in central Birmingham, there has been
a significant change in stage distribution and increase in
survival to 2 years in the patients from the study practices.
The study has demonstrated that the early investigation of
dyspeptic patients aged over 40 can increase the rate of early
gastric cancer detection to 26.8% and improve mortality from
the disease.
A survey ofthe management ofbreast cancer and attitudes toit in
one healthdistrict
M. Leslie, E.J. Maher, B. Shorey & J. Ashby
Regional Centrefor Radiotherapy, Mount Vernon Hospital,
Northwood, Middlesex, Hillingdon HospitalandBrunel
University, UK.
Hillingdon District contains a population of240,000. In a year
there are 100 new cases of breast cancer and 50 deaths. The
number of cases at any one time is 700. During the period
January 1985 to December 1986 there were 199 new cases of
breast cancer. The five surgeons in the district shared the
workload and the numbers seen by each were 58, 46, 37, 32 and
26. The percentage undergoing mastectomy was 44%. Of the
56% treated by conservative surgery 14.8% had an axillary
staging procedure. Five per cent received adjuvant
chemotherapy. The proportion receiving adjuvant hormonal
therapy was not determined. No patient was in a clinical trial.
There was no local consensus with regard to treatment.
Sixty-seven ofthe district's 121 GPs and 33 of80 community
nurses replied to a questionnaire regarding breast cancer
management. With regard to the aims oflocal therapy 20% of
GPs held the view that it was to increase survival, 45% that it
was to increase disease-free survival and 30% that it decreased
local recurrence. With regard to follow up a majority of both
GPs (67%) and community nurses (60%) felt the aim was early
detection of metastases. Views on the side-effects of
radiotherapy and chemotherapy were also explored with some
unexpected findings. In particular 17% of GPs and 24% of
community nurses felt that hair loss was an expected side effect
of radiotherapy treatment.
The results ofthis survey in one district show the lack ofany
local consensus or recognised 'specialist' surgeon and point to
some misunderstandings amongst community nurses and GPs
about aims and side effects of breast cancer treatment.
Factorsinfluencingclinicaldecision-making in the treatment of
advanced head andneck cancer
E.J. Maher& A. Jefferis
RegionalCentrefor Radiotherapy andOncology, Mount Vernon
Hospital, Northwood, Middlesex and Wexham ParkHospital,
Slough, UK.
Twenty radiotherapists and 20 surgeons were given the case
histories ofthree patients with advanced head and neck cancer,
including a man of 72 with pyriform fossa carcinoma and
bilateral nodes (1), a man of 42 with carcinoma of the tongue
and bilateral nodes (2) and a woman of 62 with recurrent
tonsillar carcinoma and contraleral nodes (3). They were asked
how they would manage them and what factors influenced
them to change their approach. Radical treatment was pro-
posed by 13 in case 1, 37 in case 2 and 23 in case 3 (39 for
surgeons vs 34 for radiotherapists). As expected, type ofradical
therapy varied. Both surgeons and radiotherapists favoured
radiotherapy (37 vs 34), while surgeons used more surgery (37
vs 20) and less chemotherapy (17 vs 9) as part of radical
treatment.
Non-TNM factors influencing a change in approach
included age, general condition, social support and persistent
smoking or drinking, e.g. while social support was very
influential for 30% of radiotherapists, 50% would not take it
into account at all in selecting for radical treatment; similarly,
'absolute cut-offs' for radical treatment in case 1 ranged from
75 to 90 years of age.
Selection for radical treatment in advanced cancer of the
head and neck involves more than TNM stage and Karnofsky
status. Subtle differences in selection criteria may significantly
bias the results ofpublished series and clinical trials. The use of
surrogate studies, together with a national data base may
clarify the decision-making process.
Lung cancerpatients: perception oftheir illness andits treatment
L. Ginsberg, C. Quirt, A.E. Ginsberg & W.J. Mackillop
Kingston Regional Cancer Centre, Kingston, Ontario, K7L 2V7,
Canada.
Forty-five patients with primary lung cancer were interviewed
within 3 months of their diagnosis to determine how they
perceived theirillness and how theirperceptionscompared with
those oftheir attending physicians. All ofthe 45 patients knew
that they had lung cancer. Twenty-six of the 45 correctly
recognised the extent of their disease as localised, regional or
metastatic. However, 16 of 25 patients with regional disease,
and two ofthe 15 patients with metastatic disease thought that
the cancer was localised. Two of the 11 patients being treated
with curative intent thought that the treatment was palliative
only, and nine of the 34 patients being treated palliatively
believed the treatment intent was cure. Seventeen of the 34
incurable patients thought that they had a chance of being
cured and 15 of these thought that the probability of being
cured was at least 50%. In every case the doctors stated that
they had accurately informed the patient about the probability
ofcure and that they thought thepatient accurately understood
the prognosis. No significant association was demonstrated
between the accuracy of the patient's perception of his or her
situation and anxiety and depression scores measured by the
Speilberger and Beck self evaluation instruments respectively.
It was concluded that while most patients with lung cancer
today recognised their diagnosis, many failed to appreciate the
gravity of their situation and grossly over estimated the
potential benefits of treatment which they are receiving.160 BRITISH ONCOLOGICAL SOCIETY MEETING
Howgood arephysicians atjudging lifequality andphysical
performance inincurable non-smallceli lungcancer(NSCLC)
patients?
J. Regan, P. Jones, N. Cooke &J. Yarnold
Academic Radiotherapy Unit, The RoyalMarsden Hospital,
Sutton, Academic Medical Unit, St George's Hospital, Tooting
andDepartment ofMedicine, St HelierHospital, Carshalton,
UK.
Forty patients with NSCLC were treated according to the
recent MRC palliative radiotherapy protocol with 20 patients
randomised to 30 Gy in 10 daily fractions and 20 patients to
17 Gy in two fractions one week apart. The physicians assessed
patient general condition, activity and respiratory status ac-
cording to the MRC protocol. Forced vital capacity (FVC),
haemoglobin and weight were also measured. The physicians
were blind to the results of these measures at the time of
assessment. Patients also completed the EORTC lung cancer
quality of life questionnaire.
The physician assessment ofpatient general condition corre-
lated well with the FVC (R = 0.64, P <0.0001). The patient
self-assessment oftheir physical condition also correlated with
the FVC (R = 0.45, P = 0.009). Physician score and patient
self-assessment ofphysical condition also correlated (R = 0.47,
P = 0.002). In contrast, patient global asssessment of life
quality did not correlate with any ofthese measures (P >0.05).
In conclusion, doctors and patients agree in their assessment
of physical condition but the doctors appear unable to judge
life quality as assessed by the patients themselves
Canoncologists predictthecourseofmalignantdisease intheir
individual patients?
Technicalradiotherapy
Clinical applications andquality control for the Clatterbridge
neutrontrials
S.W. Blake, S. Myint, R.D. Errington & H.M. Warenius
Douglas Cyclotron Unit, Clatterbridge Hospital, Bebington, UK.
Since February 1986, the Clatterbridge cyclotron has been used
to conduct clinical trials in which patients are randomised to
treatment with either photons or high energy neutrons. The
neutron beam is produced by bombarding a beryllium target
with 62 MeV protons, and the treatment unit consists of a
variable collimator mounted on a fully isocentric gantry equip-
ped with both wedges and field shaping facilities. The depth of
the 50% isodose is 16 cm for a 10x 10cm field which is
compatible with that of an 8 MV linac. Careful quality control
has been applied to both the beam parameters which affect the
dose distribution and also the patient dose distributions. A
review ofthe quality assurance results showed that the random
uncertainties in calibration, field flatness, field symmetry and
beam penetration contributed to a total random uncertainty of
1.5% to the tumour dose. For the first 100 patients, the
comparability of neutron and photon treatment plans was one
ofthe criteria for entry to the trials. A dose variation of ± 7%
throughout the target volume was the limit of acceptability,
and most plans had variations of less than ± 5%. An initial
comparison of the phase 1 treatment volumes for sites in the
pelvis resulted in values of approximately 3,300 cm3 for both
neutron and photon treated patients. It is hoped that the
improved dose distribution combined with advances in the
localisation of disease will lower the morbidity of neutron
therapy.
C.F. Quirt, W.E. Stewart, A.D. Ginsburg & W.J. Mackillop
Kingston Regional Cancer Centre, Kingston, Ontario, Canada.
Although information about prognosis and tumor response is
readily available for groups and subgroups ofpatients with the
common malignant diseases, there is no information about
oncologists' ability to predict what will become of individual
patients. We prospectively obtained attending physicians'
estimates of probability of cure for 98 patients undergoing
treatment at the Kingston Cancer Clinic. These predictions
were subsequently correlated with the outcome of the disease
process. The two-year survival rate of 56 patients undergoing
curative treatment, and of 42 patients undergoing palliative
treatment were 66.9% and 11.4% respectively (P <0.0001).
The two-year disease free survival ofa subgroup of28 patients,
whose predicted cure rate was >0% .50%, was 35.8%
compared to 85.6% for a subgroup of 28 patients whose
predicted cure rate was >50% (P <0.0001). There was a
significant correlation between predicted probability of cure
and complete response (CR) rates (predicted cure rate >0
<30%, CR = 62.5% and predicted cure rate > 30%,
CR=100%; P<0.01).
Doctors estimated the survival of 39 of the 42 incurable
patients as 0-3 months, 4-6 months, 7-12 months, I -2 years
or greater than 2 years. Twelve died within the predicted
interval, 12 died earlier and 15 lived longer than expected.
Patients expected to live for less than 6 months had a median
survival of238 days compared to 414days for those expected to
live for more than I year. The variance ofsurvival within each
group was very large and thisdifference did not reach statistical
significance (P = 0.1). Theaccuracy ofsurvival predictions was
independent of the doctor's age, sex or specialty training.
Oncologists' predictions of curability correlate well with both
complete response rates and 2-year survival rates, but estimates
of duration of survival for individual incurable patients are
usually inaccurate.
Theeffect ofvaryingdoseschedules in responseofglottic
carcinoma ofthe larynx
A.G. Robertson, C. Robertson, P. Boyle & R.P. Symonds
Beatson Oncology Centre, Western Infirmary, Glasgow, UK.
It is widely accepted that different dose-time-fractionation
schedules give rise to different acute and long term reactions.
Three hundred and ninety-three patients with carcinoma ofthe
larynx confined to the glottis were treated in Glasgow between
1958 and 1977. Six different dose-time-fraction schedules
were used during this period to treat these patients radically.
One hundred and seventy-six patients had T1 NO MO disease,
82 had T2 NO MO, and 46 had T3/T4 NO MO. Ninety-four
patients were treated using a 60 Gy, 30 fraction, 42 day
schedule; 104 with a 60 Gy, 25, 35 schedule; 38 with 54 Gy, 18,
42 schedule; 14 with 56.5 Gy, 25, 35 schedule; 24 with 61 Gy,
15, 36 schedule, and 29 with 60 Gy, 30, 49 + schedule. The
resulting morbidity, tumour control anc hence long-term
survival are presented.
For all stages patients treated with the schedule 60, 25, 35
achieved the best tumour control. Where there was a gap in
treatment, i.e. those treated with the 60, 30, 49 + schedule,
there was a definite reduction in tumour control. There was no
obvious difference in the morbidity associated with these
schedules.
Consideration ofthe cumulative radiation effects (CRE) (see
figure for all stages of the tumour) shows that tumour control
increases as CRE increases from 1,700 to 1,900 rets. Above
1,900 rets the data are not sufficiently reliable to support a
continuing increase in tumour control or to conclude that there
is a decrease in tumour control.BRITISH ONCOLOGICAL SOCIETY MEETING 161
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Three-dimensional (3D) treatment planning inradiotherapy of
brain tumours
A.M. Bidmead, V. Kaushal, L.J. Hill & M. Brada
Departments ofPhysics andRadiotherapy, The RoyalMarsden
Hospital, London andSutton, UK.
3D treatment planning enables the calculation of integral
dose-volume histograms (DVH) which give the true picture of
dose distribution in normal tissue. We analysed the DVH in
normal brain of eight patients undergoing localised external
beam radiotherapy for CNS tumours. A mean of 43%
(24-57%) of normal brain volume received more than 50%
and mean of 22% (9-38%) received more than 85% of the
maximum tumour dose. The addition of customised shielding
blocks using a 3D planning facility led to a mean reduction of
13% and 8% of the normal brain volume irradiated to more
than 50% and 85% ofthe maximum tumour dose respectively.
Dose-volume histograms demonstrate that surprisingly
large volumes of normal brain receive clinically significant
doses of radiation despite localised treatment technique.
Although the use of customised shielding blocks reduces the
amount ofnormal brain irradiated, the reduction is unlikely to
be sufficient for a significant improvement in therapeutic ratio.
Further improvement may only be achieved with more
localised delivery of radiation.
Our results show that theoc/p ratio calculated from the LQ fit
to the acute survival curves varied from 11 to 46. In contrast,
when the values were obtained as described above, we came to
the startling conclusion that the cx/p ratio is constant with a
value of 10.3 ± 1.7.
The valueofICRU38dosimetricparametersinassessingpelvic
tolerancetointracavitary therapyinearlycervicalcancer
I.H. Kunkler, A.L. Gerbaulet, G.R. Kerr& D.C. Chassagne
Institut Gustave Roussy, Paris, FranceandDepartmentof
Clinical Oncology, Edinburgh, UK.
The correlation between intracavitary (IC) dose to critical
pelvic organs and complications has previously been hampered
by inconsistent bladder and rectal reference points. Standard-
ised ICRU 38 dosimetric parameters (Kerma, intracavitary
volume (V) and maximum doses to bladder, rectum and
lymphatic trapezoid), have been correlated with pelvic comp-
lications (PC) in 453 patients treated at IGR 1975-84 with
stage I and II (proximal) ca cervix. Standard treatment with IC
therapy 60 Gy, or 40 Gy (if 20 Gy by external beam (EB)
before intracavitary therapy) and colpophysterectomy and
external iliac lymphadenectomy (CHL). Pelvic EB (20 Gy)
was given in 83 patients pre IC and postoperatively (45 Gy) in
68. PC were classified by the glossary of Chassagne. The
incidence ofPC was compared for different Kerma, IC volume
and critical organ dose levels using x2 and Kruskal-Wallis
tests (KW).
The incidence of grade I, II and III/IV complications was
45% (200), 33% (121) and 4% (21); combined complications to
the rectum 1.5% and to the bladder 3.4%. There was a
significant association between bladder reference dose from IC
and vesico-vaginal fistula (VVF) (X2, P = 0.03) and between
combined rectal complications (grades I-III/IV proctitis and
rectovaginal fistula) and rectal reference dose from IC (KW
P = 0.03). There was no association between IC dose to the
lymphatic trapezoid and the incidence of lymphocele. No
association was found between IC volume, or Kerma and
combined rectal or bladdercomplications. ICRU 38 dosimetric
parameters may provide a useful guide to predicting pelvic
morbidity from intracavitary therapy.
AIDS and sarcomas
AIDS-related lymphoma: experience at St Stephens and
Westminster Hospital
Thecellular x/Ip ratio: isit a constant?
J.H. Peacock, T.J. McMillan & G.G. Steel
Institute ofCancer Research, Sutton, Surrey, UK.
The oc/p ratio has been widely used as a measure of recovery in
both normal tissues and tumours. Values of cc and P for
tumours are usually obtained by computer-aided analysis of
dose-survival curves and for human tumour cells have varied
from 2.1 to 92 (e.g. Fertil & Malaise (1981) J. Radiat. Oncol.
Biol. Phys., 7, 621).
We have used two measures of cellular recovery in order to
derive independent measures of oa and P in 15 human tumour
cell lines ofvarying sensitivity. Using low dose-rate irradiation
(- IcGy min-') recovery was complete during irradiation and
cell survival fell exponentially with dose as a function of only
(SF = e-.D).
The value of, is related to the recovery capacity ofthe cells.
According to the linear-quadratic equation, the split-dose
recovery ratio (RR) is highly dose-dependent: RR = exp(2Pd2).
By performing split-dose experiments over a range of doses
and plotting loge (RR) against 2d2 we get a reliable value for P.
A.G. Goodman, A.M. Brunt, R.H. Phillips, M.S. Youle &
B.G. Gazzard
Department ofRadiotherapy and Oncology, Westminster
Hospital and Department ofAIDS Medicine, St Stephens
Hospital, London, UK.
Between 1986 and 1988, 11 patients (all homosexual orbisexual
men) with HIV-related systemic lymphoma were treated at St
Stephens and Westminster Hospitals. Ten patients had non-
Hodgkin's lymphoma (NHL). One had Hodgkin's disease
(HD) (stage IA). He was treated with radiotherapy and
survived 14 months before dying, free of disease, of an
opportunistic infection (01). All those with NHL had high
grade histologies, with extranodal disease in eight patients.
Two had stage I disease, four had stage IE disease (one
Waldeyer's ring, two stomach, one rectum), and four had stage
IV disease. CNS involvement was common, with meningeal
disease at presentation in two patients and at relapse in 2 more.
Unusual pain appeared to be a feature of such relapses.
Radiotherapy was given for localised disease (40-50 Gy in
2 Gy daily fractions). Mucosal and skin reactions were
occasionally severe as may be expected in HIV positive
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in standard doses for generalised disease. There was one
infective death (TB) on treatment. Overall survival has been
short, with a median of 5 months. Three deaths were due to
disease, three to 01 and one to Kaposi's sarcoma (KS). There
are two long-term, disease-free survivors, at 36 months (stage
IV) and 12 months (stage I). Two others are alive at less than 6
months, one in complete remission (CR) and one in partial
remission (PR) on chemotherapy. Further studies are required
to elucidate which patients are likely to benefit from standard
intensive treatment of such lymphomas.
The CD4 molecule: its roleintherapy and vaccine strategies in
AIDS
A.G. Dalgleish, D. Wilks, L. Walker&J. Habeshaw
MRCClinicalResearch Centre, Harrow, Middlesex, UK.
The CD4 molecule binds to all isolates ofHIV at an affinity in
excess of 109 mol. Whereas the rest of the envelope is highly
variable and elicits antibody responses which are isolates
specific, loss ofthe ability to bind to the CD4 molecule results
in a non-infectious non-pathogenic virus. Monoclonal
antibody studies show that some antibodies bind with high
affinity and block HIV fusion and infection more efficiently
than other anti-CD4 antibodies. We have therefore used one of
these antibodies, Leu 3a, to try and raise an anti-idiotype
response which should resemble the CD4 molecule. More
recently numerous soluble CD4 preparations have been made
and these have been able to neutralise all HIV isolates and
appear to have no detrimental effect in immunological assays
either in vitro and in vivo.
Using an Allum precipitated immunisation schedule the
monoclonal antibody Leu 3a has been able to raise polyclonal
response which has weak antiviral activity using a fusion
plaque assay system. The antiviral titres are in the region of
1-200 whereas the background is 1/50 to 1/100. However, by
diluting the internal image response we have been able to show
that this activity is not a specific anti-idiotypic response.
Mapping ofLeu 3a to CD4, as well asCD4 mutants, show that
it is closest to the gpl2O binding site and more closely resemble
gpl20 binding that other available monoclonal antibodies. A
similar trial in human patients with ARC without using an
adjuvant has led to the successful induction of specific anti-
idiotypic responses in these patients. There has also been no
shoter intermediate adverse effects from this schedule. Again,
no specific antiviral activity has been detected in these patients
over and above their natural immunity.
Recent construction of CD4 human immunoglobulin hy-
brids has shown that only the part ofCD4 which is recognised
by Leu 3a and similar monoclonal antibodies is required to
effectively neutralised all HIV isolates. The above studies show
that although close Leu 3a is not the ideal immunogen and we
are now engaged in searching for an anti-CD4 immunogen
which would raise the idiotype recognised by the CD4 human
IgG hybrid, which could clearly be a vaccine strategy which
would protect against all isolates.
Radiation therapy forAIDS related Kaposi'ssarcoma
A.M. Brunt, A.G. Goodman & R.H. Phillips
Radiotherapy department, St Stephens and Westminster
Hospitals, London, UK.
Kaposi's sarcoma is diagnosed in almost 40% ofpatients with
AIDS at our institution. One hundred and ninety-four cases
were diagnosed by the end of 1988. These patients have a
median survival of20 months, and where the cause ofdeath is
known 38.6% died directly due to the Kaposi's sarcoma and in
a further 11.4% it was considered to be an important cont-
ributing factor. We aim to palliate the disease where indicated.
The indication for radiotherapy in ourdepartment has been for
cosmesis in 63.5% and for pain and functional complaints in
the remainder. The lower limb and the head and neck (ex-
cluding the oral cavity) comprise over two thirds ofthe treated
sites. The majority of treatments are with superficial X-rays,
though megavoltage X-rays are used when indicated. We
report the largest British series to date: 74 patients received a
total of 352 courses of radiation therapy up to 31 December
1988. Response is assessed on a five point scale; complete
response with and without residual pigmentation, partial res-
ponse, static disease and progression. The response is assessed
at 1, 3 and 6 months with 51.5% achieving a complete and
15.9% a partial response at 3 months and 53.6% of lesions
assessed at 6 months exhibiting a complete response. The
majority of treatments have been given using either a single
fraction of 800cGy or 10 fractions of 180-200cGy, these
regimes are compared as showing no significant difference.
Radiotherapy is well tolerated except for the severe mucositis
often observed when treating the oropharynx.
The resultsoftreatment of102patientswithlocally recurrent
softtissuesarcoma
M.H. Robinson, C. Fisher, C.L. Harmer& G. Westbury
Sarcoma Unit, RoyalMarsden Hospital, UK.
The results of treatment of 102 patients with locally recurrent
non-metastatic soft tissue sarcoma (STS) are reported. Thirty-
two tumours were situated in the lowerlimb, 24 the upperlimb,
22 pelvic and shoulder girdle, eight trunk, seven abdomen, and
nine head and neck. Histology comprised MFH 32 cases,
liposarcoma 22, synovial sarcoma 12, others 36. Fifty-seven
were high grade, 21 intermediate and 24 low. Grade increased
in six and decreased in seven patients with recurrence. The
median size of tumour at presentation and at first local
recurrence was 5 cm. Surgical clearance of the first local
recurrence was 'adequate' (Enneking) in 39% of assessable
patients, including 8/12 amputations, but in only 18% of the
original operations which included two amputations. Thirty-
three patients were irradiated as part of the treatment of the
primary disease, only two of whom had had an 'adequate'
surgical clearance. Thirty-two patients were given radiotherapy
following first local recurrence. For six patients this involved
re-irradiation. Median follow-up was 36 months. Actuarial
local control ofthose with 'adequate' surgical clearance oftheir
first local recurrence was 80% at 2 yearscompared with 55% in
those with 'inadequate' clearance (P <0.025). Survival (85%
vs 65%) was also significantly different (P <0.025). Local
control and survival were significantly better in those with
upper or lower limb tumours compared to other sites. Local
control at 2 years (70% vs 45%) was significantly better in
those receiving radiotherapy as part of the treatment of their
first recurrence (P <0.025). Survival and local recurrence were
significantly worsened by tumour size > 10 cm but not grade.
The roles of surgery and radiotherapy in the management of
recurrent STS will be discussed.
Thespectrum ofhistologicalresponse topreoperative
chemotherapy inprimarymalignantbone tumours
J.A.S. Pringle & R.L. Souhami
London Supra-regionalBone TumourService, London, UK.
Recent advances in the treatment ofprimary malignant tumour
of bone have included chemotherapy given before and after
surgery and in many cases local resection and prosthetic
replacement ratherthan amputation. The types ofbone tumour
treated in this way include high grade osteosarcoma (central
and surface), periosteal osteosarcoma, Ewing's sarcoma, and
malignant fibrous histiocytoma (MFH). The problems
encountered by the pathologist vary in each tumour type. InBRITISH ONCOLOGICAL SOCIETY MEETING 163
osteosarcoma there is a wide spectrum of'response' which falls
short of necrosis and may give the appearance of 'increased
differentiation'. In Ewing's sarcoma, response is often
associated with much reactive bone formation and micro-
deposits of viable tumour may be seen microscopically where
the clinical and radiological response appears complete.
Periosteal osteosarcoma responds by increasing mineralisation,
but rarely by complete necrosis. While with MFH, reparative
fibroblastic tissue may be difficult to distinguish from residual
fibroblastic tumour. This study confirms that these four
categories of primary bone tumour are chemosensitive and
although response may fall short ofthe 90% necrosis accepted
as likely to indicate good prognosis, a more modest response
associated with increased mineralisation may enable the
surgeon to perform limb-sparing surgery.
Biology
dimunition ofthe leucocytosis, and led to a fall in haemoglobin
and platelet counts (P <0.005). A significant rise in peritoneal
Thy 1.2 positive cells was noted at 3 weeks. Scheduling
experiments show that daily therapy was not necessary and
equivalent survival benefit was gained with three times a week
treatment or once weekly high dose (7rig) treatment. Contrary
to thesepositive effects on survival, post-mortems revealed that
while TNF caused necrosis offree floating peritoneal tumours,
it increased the mesothelial hyperplasia induced by xenografts,
and led to invasion ofthe peritoneum by the tumours. This was
also seen in the OS xenograft which was resistant to TNF
therapy. These results may suggest a role for endogenous TNF
production in peritoneal metastasis.
Proliferation inhuman tumoursmeasuredby Ki67antibody
labelling: itspotentialclinical use
P. Price, C. Bush, J. Norton, C. Jones, M. Bailey, C. Parkins,
M. Robinson, P. Blake &A.H. Horwich
Enhancement oflung metastases by interferon-y
S.A. Kelly & F.R. Balkwill
Imperial Cancer Research Fund, London, UK.
Incubation of a lung colonising variant of Colon26 (an
undifferentiated murine colone adenocarcinoma cell line) in
vitro with rMuIFN-y, but not rIFN-axA/D, leads to a significant
increase the number oflung colonies in syngeneic BALB/c mice
in an experimental metastasis assay. (Median number of
colonies: control, 22; rIFN-aA/D 18; rMuIFN-'y200.) A I hour
incubation is sufficient to see this enhancement.
Following i.v. injection all cells are found in the lungs, but
control and rIFN-aA/D pretreated cells are cleared at a
significantly faster rate than those pretreated with rMuIFN-y.
The differences are mainly seen in the first 24 hours following
injection. This implicates NK killing, and we have some
evidence to support this in that in models where animals are
depleted of NK cells (beige nude mice, and anti-asialo GM-1
treated mice) the enhancement of metastases by IFN-y is not
seen. However, Colon26 do not form conjugates with NK cells
and are completely resistant to NK lysis in vitro.
Some investigators have correlated an enhancement ofclass
1 MHC by interferons with increased resistance to NK lysis,
and suggested that this is the mechanism of enhancement of
metastatic potential. This is unlikely to be the case in our
model, since both interferons equally enhance class 1 MHC.
Paradoxicaleffects ofTNFinintraperitoneal (i.p.) human
ovarian cancer xenograft models: prolongation ofsurvival and
enhancement ofmetastasis
S.T.A. Malik, D.B. Griffin & F.B. Balkwill
Imperial Cancer Research Fund, PO Box 123, Lincoln's Inn
Fields, London WC2A 3PX, UK.
The effects of i.p. therapy with low dose (1 fig daily) recom-
binant human TNF was investigated in three intraperitoneal
human ovarian cancer xenograft models (OS, LA and HU).
Parameters studied included: (a) effect on survival; (b) sequen-
tial cytological immunophenotypic analysis of blood and
peritoneal cell populations (PEC); (c) sequential analysis of
macroscopic and microscopic tumour in the peritoneal cavity
and peritoneal biopsies; and (d) variations of dose-schedule
regimes. TNF prolonged survival in the HU and LA xenografts
(median survival: control HU = 22 days; TNF treated
HU = 52 days (P <0.001); control LA = 22 days, TNF
treated LA = 52 days (P <0.001)). No survival benefit was
seen in the OS xenograft. The major change in the peripheral
blood and PEC was a neutrophil leucocytosis, which was
greater in tumour mice (P <0.01). Daily therapy led to
Radiotherapy Research Unit, InstituteofCancer Research and
RoyalMarsden Hospital, London andSutton, UK.
The monoclonal antibody Ki67 recognises a human nuclear
antigen expressed in proliferating cells. This antibody has been
used to assay the proliferative fraction (PF) ofprimary bladder
and cervical tumours. This technique carries the advantage of
not requiring prior injection of thymidine anologues, only
requiring small amount of fresh tissue and material can be
collected at routine biopsy. Biopsies have been obtained from
27 patients with bladder cancer and 22 with cervical carcinoma.
Tumour specimens were snap frozen and then cryostat sections
were stained with Ki67 using an indirect immunoperoxidase
method. Ki67 positive nuclei were counted under light micro-
scopy and a Ki67 PF (the number ofKi67 positive tumourcells
divided by total number of tumour cells %) was derived by
counting > 500 tumour cells per sample. Intrasample variation
was < 5%. A wide range of Ki67 PF were detected, ranging
from 7.4 to 65.8% for bladder carcinoma and from 2.4 to
46.8% for the cervical carcinomas. Ki67 PF correlated with
known prognostic factors: TNM stage and grade for bladder
carcinoma and Figo stage and histological grade for cervical
carcinoma. Three bladder patients had metastases at presenta-
tion and two of these had the highest Ki67 values. Further
follow-up is required before the Ki67 PF can be evaluated as an
independent prognostic variable and as a predictor for res-
ponse to radiotherapy.
Analysis ofgeneregulation in teratocarcinomastem cellswith the
episomal plasmid, Lfactor
M.J.C. Ellis & S.E.Y. Goodbourn
Gene Expression Laboratory, ImperialCancerResearch Fund,
Lincoln's Inn Field, London WC2, UK.
Germ cell tumours are striking examples of how normal
differentiation can be disrupted by malignant transformation.
Instead ofproducing gametes, these tumours give rise to tissues
exhibiting features of embryonal development. Cell lines
derived from both murine and human germ cell tumours can be
induced to differentiate in vitro by exposure to retinoic acid. In
order to investigate the molecular basis of how genes are
regulated during teratocarcinoma stem cell differentiation we
have stably introduced test genes into undifferentiated mouse
F9 teratocarcinoma cells using the episomal vestor L factor, a
plasmid related to polyoma virus that replicates extrachromo-
somally as closed circles of DNA (Nashimori et al., Mol. Cell
Biol., 8, 2097). The activity ofthe test gene was followed during
retinoic acid induced differentiation using a sensitive RNA
mapping technique. We have demonstrated that the
inducibility by double-stranded RNA of an L factor linked
P-interferon gene mirrors the increasing inducibility of the164 BRITISH ONCOLOGICAL SOCIETY MEETING
endogenous mouse beta interferon gene during F9
differentiation. Viral enhancer elements linked to L factor also
become activated in a manner which parallels the behaviour of
these elements in intact viral genomes. By mutating key
regulatory sequences and introducing them into this system we
have a powerful method for investigating how differentiation
specific gene expression takes place and how it may be
disrupted by malignant transformation.
Bone resorbing tumoursinhibit thegrowth and function of
osteoblast-like cellsin vitro
C.E. Evans, C.S.B. Galasko & C. Ward
University ofManchester, UK.
The destruction of bone is normally accompanied by reactive
new bone formation. This occurs with nearly all metastases, but
notwith most myelomata, which producelyticlesions which do
not concentrate bone-seeking isotopes. We have developed a
bioassay usingcells grown from human cancellous bone (BDC)
to examine the effect of myeloma on osteoblast-like cells.
Previous studies have shown that these cells exhibit a range of
osteoblast-like characteristics. Two myeloma cell lines
(GM1500 and Karpas) were cultured in vitro, plus myeloma
tissue from a patient with myeloma (McA). Culture medium in
which these cells had been grown (MCM) was used in the
bioassay; BDC were cultured with either MCM or a control
medium. Two parameters ofcell growth, cell numberand DNA
synthesis, were assayed after the BDC were incubated with the
MCM for 48 hours. MCM from GM1500 caused a mean
decrease of29% in cell number and of47% in DNA synthesis.
Control experiments demonstrated that this was not due to a
general, cytotoxic effect. Incubation of BDC with medium
conditioned by other BDC, or by skin fibroblasts (FB) did not
show such inhibition. Similarly, no inhibition was seen of FB
incubated with MCM. Also, the inhibition of BDC by MCM
was density and dose-dependent. MCM from McA and from
Karpas cells inhibited cell numbers by 18% and 31% respec-
tively; DNA synthesis was inhibited by 71% and 17% respec-
tively. Similar inhibitory effects, seen with MCM from another
bone-resorbing tumour, breast carcinoma, are still under in-
vestigation. These results confirm that myeloma secretes an
osteoblast-inhibiting factor(s) and explain why myeloma is
different to other bone-resorbing tumours, and why scinti-
grams are frequently negative.
Reconstruction and restoration of function in
cancer surgery
Reconstruction in the head and neck
N.M. Breach
Royal Marsden Hospital, London, UK.
Reconstruction of the head and neck has to encompass the
functions of the part: respiration, mastication, swallowing,
speech and cosmesis. Following the excision of tumours,
restoration of function requires the replacement of that part
which has been removed. The concept of reconstruction has
changed in recent years as knowledge of the blood supply to
the skin has reduced it from a multistaged procedure to a
single operation, through the use of myocutaneous and free
flap transfer.
Problems of colour match, skin quality and function
bedevil the reconstructive surgeon. The introduction of dis-
tant flaps to the face results in a patch-like deformity. The
thickness of the subcutaneous tissues may vary giving prob-
lems of bulk. External skin is frequently used to replace the
mucosa; in this situation the flap will be non-sensory, non-
secretory, possibly hairy and immobile, whereas the mucosa
is sensate, does secrete, does not grow hairs and is mobile.
Oral and pharyngeal reconstruction must be considered as
a three-dimensional concept. Frequently a single flap is used
in the repair, which may result in the limitation of function.
Examples will be shown to illustrate the modern concept of
reconstruction with particular reference to the single staged
compound flap repairs.
Reconstructive surgery for primary malignant tumours of bone
H.B. Kemp
Royal National Orthopaedic Hospital, London, UK.
Before the introduction of specific cytotoxic therapy by
Rosen et al. (1979), the only available surgical treatment of
malignant bone tumours was amputation. Even the more
refined combination of radiotherapy and interval amputation
advocated by Stanford Cade (1955) only marginally im-
proved the 5-year survival rate above 10%.
Cytotoxic therapy facilitated a more conservative approach
to these forms of malignant disease. In France, Merle
d'Aubigne (1958) advocated resection and reconstructive
auto grafting; in the USA, Henry Mankin and others (1956)
used cadaver bone as homografts, while in Germany,
Winkelmann (1983) resected the tumour approximating the
residual bone and with lesions of the lower limb rotated the
distal part through 180 degrees so that the ankle could be
employed as a knee joint (rotation turniplasty). All these
methods were excellent in concept; the disadvantages were
the length of time that elapsed before the limb could func-
tion. Function was necessarily of limited achievement.
In this country, Burrows et al. (1975) had already had
experience in the treatment of chondrosarcoma and extensive
benign tumours, replacing the affected bone and associated
joint with an internal prosthesis. With the advent of bone
cement more sophisticated fixation of the prosthesis was
achieved. In consequence, over 1,000 bone tumours have
now, in the short-term, been successfully treated in the two
supra-regional centres.
Today, due to the use of cytotoxic therapy in conjunction
with surgery, the survival rate of patients with Ewing's sar-
comas and osteogenic sarcomas is in the region of 60%.
This particular method for treatment has certain disad-
vantages. Prosthetic loosening and prosthetic fracture are
now essentially minor problems, but the risk of infection in
patients who are immunologically compromised as a sequel
to cytotoxic therapy must obviously remain high and,
although the majority of infections respond adequately to
antibiotic therapy, 2% of patients will develop extensive
osteomyelitis necessitating amputation. The advantage of this
form of management is that the patient can be rapidly
rehabilitated to near normal function and the body image is
maintained, a feature of some consequence to the adolescent
and young adult.
Reconstructive urology
C.R.J. Woodhouse
Royal Marsden Hospital, St George's Hospital and The
Institute ofUrology, London, UK.
Reconstructive urology in this context means provision of a
neo-bladder which is continent and which is usually emptied
by intermittent clean self-catheterisation (ICSC). Experience
in children and adolescents has shown that no patient need
have an external urinary diversion with a bag. The question
now arises when and how the same should be applied to the
cancer patient. Reconstruction should not be confined to a
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'Mainz'. Three mutually independent components are neces-
sary: a container for the urine, a means to conduct the urine
to the surface and a continence mechanism. One or more
items for each of the components may be selected from the
lists in the table and used for reconstruction tailored to the
patients needs.
Container: Bladder, stomach, ileum, caecum, colon
Conduit: Urethra, appendix, fallopian tube, ureter, skin tube,
ileum, stomach tube
Continence mechanism: Urethral sphincters, detrusor tube, artificial
sphincter, Kock nipple, Mitrofanoffprinciple, ileocaecal
valve, anal sphincter
processes which have been necessary in the surgical treatment
of sarcomas, melanomas, breast cancers and cloacal tumours
extensively involving perineal skin.
Central nervous system malignancy
Pineal and CNS germ cell tumours. Royal Marsden Hospital
1962-1987
S.J. Whitaker, R.P. A'Hern & D.P. Dearnaley
Royal Marsden Hospital, London and Sutton, UK.
As much as possible of the natural urinary tract should be
included. Otherwise my first choices are large bowel for the
pouch, appendix for the conduit and the Mitrofanoff prin-
ciple (tunnelling a narrow tube such as the appendix into the
wall of the pouch) for continence. The surgeon's selection of
patient is the relatively fit, thin, well motivated and poten-
tially curable - about 50% of patients. The patient may be
unwilling to risk the additional surgery required for recon-
struction or may not like the idea of ICSC. This eliminates a
further 25%. Ten of 39 continent diversions in my series have
been in cancer patients. Two died in the immediate post-
operative period although in only one was the reconstruction
a contributory cause. Three patients have had delayed
recovery. One patient has had a revision for difficulty with
catheterisation. Major series throughout the world report a
complication rate of about 25% with an acceptance rate by
the patients between 15 and 98%. There has been general
acceptance by the patients and hospital staff of the
superiority of reconstruction over an external bag but selec-
tion must be meticulous.
Reconstruction and the surgical oncologist
J. Meirion Thomas
Pineal and intracranial germ cell tumours are rare, compris-
ing less than 1% of all primary intracranial malignancies. We
present a retrospective analysis of cases presenting to the
Royal Marsden Hospital between 1962 and 1987, document-
ing prognostic factors, patterns of relapse and survival
together with an assessment of quality of life and initial
results with platinum containing chemotherapy.
Sixty-eight cases were seen after initial presentation and were
divided into three groups: (1) germinoma (36 cases), (2)
malignant teratoma (11 cases), and (3) non-germ cell tumours
(21 cases). Germ cell tumours were treated with whole CNS
irradiation (tumour dose 51 Gy, whole brain and spine dose
30 Gy over 8 weeks), and radioresistant tumours with local RT
fields (50 Gy over 7 weeks). Eight patients received cisplatin
containing chemotherapy.
Cause specific 5 and 10 year survival was 84% in ger-
minoma, 20% for malignant teratoma and 64% and 47%
respectively for non-germ cell tumours. Neurological status
of survivors was good with 86% MRC grade 1 or 2, and
66% had normal schooling and 76% obtained normal em-
ployment. Thirty eight percent required hormone replace-
ment. Cisplatin containing chemotherapy produced two CR
and six PR.
Whole CNS RT produces excellent survival and good
quality of life for germinomas but the treatment of CNS
teratomas is unsatisfactory. The role of platinum containing
chemotherapy and aggressive surgery remains to be defined
in this group.
Westminster and Royal Marsden Hospitals, London, UK.
Immediate reconstruction following either curative or pal-
liative cancer surgery offers enormous advantages. The
knowledge that a safe, simple and reliable method of recon-
struction is available allows the surgeon to resect tumours
with a wide margin of clearance. This is particularly impor-
tant in the treatment of post-irradiation recurrent tumours
where the anatomical limit of the tumour may be difficult to
define and where surrounding disease-free but irradiated tis-
sues heal notoriously badly. The transfer of healthy, un-
irradiated and well-vascularised tissues into an irradiated
wound allows wound closure without tension, accelerates and
greatly improves the chances of primary healing, protects
against infection and fills spaces where damaging
haematomas might have collected. New reconstructive tech-
niques which have come into common use over the past
decade have enhanced the scope of surgical oncology. Multi-
staged reconstructive techniques are rarely necessary and
patients can be offered immediate reliable reconstruction
thereby reducing morbidity and time in hospital. The pur-
pose of this symposium is to describe the reconstructive
techniques available and illustrate their place in patient man-
agement. Skin and soft tissue is the main requirement follow-
ing ablative surgery and the various myocutaneous transposi-
tion techniques will be described but occasionally blood
vessels, nerves, bone and joints need reconstruction. Recon-
struction is most often required for post-irradiation recurrent
tumours and this presentation will describe reconstructive
The late effects of cerebral irradiation
R.P. Beaney, D.J. Brooks & T. Jones
QEH, Birmingham and Hammersmith Hospital, London, UK.
The purpose of this study was to examine the late effects of
cerebral irradiation. The aim was to establish whether parti-
cular parts of the brain showed a predilection for radiation
damage; and if damage was demonstrable ascertain ifchronic
ischaemia played a role in its pathogenesis.
Five patients with gliomas (two grade III astrocytoma, two
grade II astrocytoma and one oligodendroglioma) were
studied at least 12 months after irradition (mean 18 months).
The patients tumour volume received 60 Gy in 30 fractions
over 42 days. The technique of positron emission tomo-
graphy was used to study regional cerebral blood flow (rCBF),
regional metabolic rate for oxygen (rCMRO2) and fraction of
oxygen extracted from the arterial blood (rOEF). There were
marked regional variations.
Our results show that abnormal brain expresses late radia-
tion damage more readily than normal brain and white mat-
ter more readily than grey matter. Ischaemia (inappropriately
low blood flow for local metabolic demands) cannot be the
main reason for the late radiation effects because the rOEF
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CBF CMRO2
(ml 100 ml- min-') OEF (ml of 02 l(J ml0
Imin-')
Tumour 9.5 ± 2.6 0.42 ± 0.03 0.64 ± 0.23
Perifocal oedema 11.8 ± 1.9 0.38 ± 0.05 0.82 ± 0.19
Irradiated white 13.9 ± 2.6 0.43 ± 0.03 1.04 ± 0.18
Remote white 20.2 ± 3.5 0.41 ± 0.05 1.42 ± 0.52
Irradiated grey 29.6 ± 4.6 0.43 ± 0.03 2.24 ± 0.32
Remote grey 31.7 ± 4.0 0.42 ± 0.02 2.31 ± 0.21
Brain tumour imaging with positron emission tomography
(PET) using F18 5-fluoro-2-deoxyuridine (FUdR)
S. Gill, C. Wilson, J. Heather, F. Brady & T. Jones
MRC Cyclotron Unit, Hammersmith Hospital, London
W12 OHS, UK.
The use of 18F-fluoro-2-deoxyuridine (FUdR) and PET to
outline tumour boundary and to estimate tumour prolifera-
tion is being evaluated. Fourteen patients (nine high grade
(3-4 glioma, three low grade (2) glioma, one cerebral lym-
phoma, one cerebral metastases) have been investigated.
seven patients were imaged with CT and PET in a relocatable
stereotactic frame allowing precise three-dimensional
measurement. A biopsy trajectory was planned using CT and
PET generated co-ordinates and serial biopsies taken from
the edge through the tumour. Histological examination to
define the tumour extent and ki67 antibody labelling to
evaluate proliferative capacity were performed. Both scans
were reconstructed along the place ofbiopsy trajectory allow-
ing pixel by pixel comparison with the biopsy material. In
this series of patients a close correlation was found between
tumour boundaries defined by PET and histology. This was
not the case with CT images. There is also accurate matching
of the labelling index of the tumours with tracer uptake in
that highly proliferative area show the greatest signal. No
signal is seen in low grade gliomas, and no specific uptake
was obtained in the patient with cerebral metastases.
Spinal cord ependymoma
S.J. Whitaker, E.M. Bessell, H.J.G. Bloom & M. Brada
The main problem in the management of spinal cord epen-
dymoma is failure of local control. It is related to tumour
grade and the extent of resection. RT may improve local
control in incompletely excised tumours.
Single dose prophylactic cranial irradiation (PCI) for small cell
lung cancer (SCLC)
P.A. Burt, N. Thatcher & R. Stout
Manchester Lung Tumour Group Christie Hospital, Manchester
M20 9BX, UK.
Two hundred and fourty eight patients with limited-stage
(LS) SCLC have been treated since 1981 using short intensive
chemotherapy and thoracic irradiation in a 3-6 month
regimen. PCI was not given.
The first 129 patients had a complete remission rate (CR)
of 55% with a 2-year survival of 10%. Relapse in the brain
occurred in 20% and it was the only site in 9%.
Between 1984 and 1986, the CR rose to 70% and the
2-year survival to 25% with improved chemotherapy. A
parallel rise in cranial relapse was noted, 36% overall and
15% as the sole site.
Conventional schedules of PCI have not demonstrated any
improvement in long-term survival. In 1986 we included PCI
in an unconventional form, giving a single fraction at 8 Gy
(800 cGy) using a parallel opposed pair 48 h after the first
course of chemotherapy. Of 33 patients (LS) treated the
2-year survival is 33%. The cranial relapse rate is 12%
overall and 9% as sole site. This represents a significant
reduction in cranial relapse which may have contributed to
the overall improvement in survival.
Academic Radiotherapy Unit, The Royal Marsden Hospital,
Fulham Road and Sutton, UK.
The aim was to define the natural history of spinal cord
ependymoma and the criteria for treatment.
Retrospective review of 52 patients with histologically
verified spinal cord ependymoma treated at the Royal Mars-
den Hospital and Atkinson Morley's Hospital between 1951
and 1987. Patients were aged 1.5-80 years, (median 40); six
had cervical, seven thoracic, 15 conus medullaris, 20 cauda
equina and four more than one region of cord involvement.
Forty three were low, five high grade and four ungraded.
Progression was defined as worsening ofclinical signs with or
without radiological confirmation. Median follow-up was 70
months (3-408).
Twelve patients had complete, 30 partial excision and 10
biopsy only; 41 patients received postoperative radiotherapy
(RT): 28 received RT to the primary site alone (5OGy), 13
had whole neuraxis RT (30-35 Gy) followed by boost
(15-20 Gy). Four patients also received adjuvant
chemotherapy.
Thirteen of 40 patients with residual disease progressed.
The 5 and 10-year progression-free survival (PFS) were 73%.
Following complete excision the progression rate was low.
PFS was worse with high compared to low grade tumours.
The 10-year cause specific survival was 73%.
Genito-urinary and gynaecological malignancy
Low toxicity platinum combination chemotherapy (PMO) for
urothelial cancer
J. Gildersleve, D.P. Dearnaley, A. Horwich, J.W.A. Ramsey,
W.F. Hendry, R.W. Shearer & C.R.J. Woodhouse
Royal Marsden Hospital, Sutton and St Bartholomew's
Hospital, London, UK.
Metastatic transitional cell cancer (TCC) of the bladder is
sensitive to chemotherapy but high response rates (Harker et
al. (1985) J. Clin. Oncol., 3, 1463; Sternberg et al. (1988) J.
Urol., 139, 461) have been associated with marked toxicity.
We have developed a less intensive schedule and report
preliminary results.
Forty-six patients with metastatic or locally advanced car-
cinoma of bladder (43), TCC of kidney (2) or ureter (1) were
treated. Median age was 69 years. Thirty-four patients had
recurrent disease, the other 12 presenting with locally
advanced or metastatic disease. Chemotherapy (PMO) was
given with cisplatin 60 mg m 2, methotrexate 60 mg m 2 andBRITISH ONCOLOGICAL SOCIETY MEETING 167
vincristine 2 mg on a 21 day schedule. Carboplatin was sub-
stituted for cisplatin if EDTA <55 ml min-'.
Subjective toxicity was mild. Of chemotherapy courses
4.7% were associated with WBC <2, with only two episodes
of neutropenic sepsis. EDTA fell 13 ml min-' per course of
cisplatinum. CR occurred in 13% and PR in an additional
22%. Response by site of disease was lymph nodes 63%,
lung 36%, bladder 33%, liver 25% and bone 19%.
PMO chemotherapy can be safely delivered to a relatively
elderly and frail population of patients with advanced TCC
and is presently under assessment by the Co-operative
Urological Cancer Group (CUCG).
The significance of dose, nodal irradiation and other factors
upon outcome after radiotherapy for bladder cancer
R.P. Symonds, S.E. Davidson, T. Habeshaw,
A.G. Robertson, M.P. Snee & E.R. Watson
Beatson Oncology Centre, Western Infirmary, Glasgow, UK.
To try to improve local control and survival we have
included pelvic lymph nodes within the irradiated volume for
part of the treatment and gradually increased the dose to the
bladder. Between 1978 and 1984, 731 patients were treated
with curative intent. Three hundred and thirty-six had
radiotherapy (4 MeV) to only the bladder and 395 irradiation
of the pelvic lymph nodes (40-42.5 Gy in 20 fractions). We
have compared retrospectively local control and survival of
similar sequential groups of patients receiving 60 Gy,
62.5 Gy, 64 Gy and 72 Gy (split course) in 30 fractions. The
overall actuarial 5-year survival was 30.9%, by stage as
follows: Tl (86.9%), T2 (49.1%), T3 (27.4%) and T4 (2.2%).
Nodal radiotherapy had no effect upon survival, stage for
stage survival was identical but serious complications were
increased (9.6% nodal radiotherapy vs 4.3% bladder only).
There is a tendency which is not statistically significant for
increased local control with higher doses but survival is very
similar in all groups. If a gap of 2-3 weeks is included in the
treatment schedule survival is reduced from 35.3% to 21.5%
(P = 0.001). The most important prognostic factors are not
differences in radiotherapy technique but biological
parameters such as tumour stage, histology, degree of
differentiation and patient age.
Stage I and II carcinoma of the cervix treated by preoperative
irradiation and Wertheim's hysterectomy
H.F. Hope-Stone
Department ofRadiotherapy and Oncology, The London
Hospital, London, UK.
Early carcinoma of the cervix can be treated by surgery or
radiation alone or by a combination of both. This paper
describes a large series of patients treated by preoperative
intracavity irradiation followed by immediate Wertheim's
hysterectomy. After initial staging, a Curietron after-loading
technique is used: a plastic intra-uterine tube is placed in the
cervix and is attached to a vaginal applicator. The whole
apparatus is held in place by a harness attached to a body
corset. X-ray pictures are taken (using dummy wires) on a
treatment simulator in the radiotherapy department. The
patient is then connected to the Curietron and stays in a
single fully-protected room for the duration of treatment.
The caesium dose rate is relatively high, and allows a dose of
2,900 cGy at point A to be given in 40 h. A second insertion
is carried out one week later, giving the same dose. Twenty
four hours after the second insertion is completed a Wer-
theim's hysterectomy is carried out, with a meticulous lymph
node dissection aided by preoperative lymphangiography and
radiological operative survey to remove any remaining lymph
nodes. If the pathology report shows lymph node involve-
ment by tumour, then post-operative external irradiation is
given to the pelvis, with a pair of opposed fields to give a
tumour dose of 6,000cGy (from a combination of the pre-
operative Caesium and the external irradiation) in 20
treatments. The rectum is protected by a mid-line parametrial
wedge lead shield. The 5-year survival figures for stage I and
II tumours are 94% in 143 cases; 23% showed lymph node
involvement. There was no major post-irradiation or surgical
mortality; the fistula rate was nil.
Prostate specific antigen (PSA) and bone scintigraphy in the
diagnosis ofprostatic malignancy
R.J. Iorns, M.A. Macleod & I.L. Jenkins
Department ofNuclear Medicine, Royal Naval Hospital,
Haslar, Gosport, UK.
Prostate specific antigen serum assay has been successfully
used as an indicator of prostatic malignancy for several
years. In addition it has been claimed that PSA values are
raised in cases of benign prostatic hyperplasia, thereby in-
creasing the level of false positive values for malignancy. In
this study we have compared PSA assay levels with bone
scintigraphy in known cases ofprostatic adenocarcinoma and
benign prostatic hyperplasia.
Data on 67 cases of histologically defined adenocarcinoma
(ADC) and 73 cases of benign prostatic hyperplasia (BPH)
are presented. In patients with ADC the PSA level was
normal in six (9%), equivocal in eight (12%) and raised in 53
(79%). Of the 45 bone scans performed in this group 29 were
positive for metastases and 16 negative. In the group with 29
positive scans the PSA was raised in 23 cases, equivocal in
three and normal in three cases. In the 73 cases of BPH, PSA
levels were normal in 30 (41%), equivocal in 25 (34%) and
raised in 18 (25%) cases. Only six bone scans were performed
in this group of 73 patients with BPH, five of which were
positive for metastases and one negative. Of the five positive
bone scans PSA was raised in four and equivocal in one case,
while in the negative bone scan the PSA was normal. We
conclude that PSA is a sensitive indicator for prostatic malig-
nancy and we intend to investigate further, patients with a
diagnosis of BPH as the results suggest the possibility that
these cases may in fact have underlying malignancy and a
raised PSA serum value cannot be dismissed as a false
positive.
An evaluation of peritoneal lavage cytology in the detection of
residual epithelial ovarian cancer
C.W.E. Redman, E. Nicholl, S.Y. Chan, E.J. Buxton,
G. Blackledge & D.M. Luesley
Dudley Road Hospital, Birmingham, UK.
As epithelial ovarian cancer (EOC) is largely confined to the
peritoneal cavity, peritoneal lavage fluid (PLF) cytology may
detect otherwise occult small volume disease. The use of
indwelling peritoneal catheters and intermittent percutaneous
cannulm primarily for IP treatment has enabled diagnostic
peritoneal lavage to be performed repeatedly on an out-
patient basis. Of 207 PLF samples obtained from 86 EOC
patients, 190 (92%) were suitable for cytological analysis
whereas 17 were acellular. Sixty-seven EOC patients with
residual disease prior to treatment had PLF samples suitable
for cytological analysis and serum CA125 estimations and 51
of these patients had end of treatment samples. Thirty
patients (45%) had small volume (<2 cm) residual disease at
the end of the primary laparotomy. Fifty-three patients had
advanced disease (FIGO stage III or stage IV). Peritoneal
cytology was positive in 38 samples (57%) and demonstrated
disease in four patients who were clinically and radiologically
free of disease. Clinical and cytological findings alone had a168 BRITISH ONCOLOGICAL SOCIETY MEETING
sensitivity of 72% (48/67) while serum CA125 levels were
raised in 58 (87%) patients. The presence of malignant cells
in pre-treatment peritoneal lavage fluid was a major adverse
prognostic factor. Thirty-one patients had positive cytology
(53%) of which only four patients (32%) were alive at 12
months compared to 20 out of the 28 (71%) cyto-negative
patients. Twenty-two patients had malignant cells in PLF
following treatment and 20 (91%) of these patients have
relapsed and died. Eleven patients had positive cytological
findings in the absence of positive clinical or radiological
findings. Of the nine patients who have relapsed (median
time to relapse = 4.5 months, range = 1.6-16.9 months), all
had elevated serum CA125 levels. Peritoneal cytology can
detect clinically and radiologically occult disease but confers
no advantage over serum CA125.
Lymphomas
Long-term follow up of BNLI study of CHOP chemotherapy
in patients with advanced high grade non-Hodgkin's lymphoma
G. Vaughan Hudson, D.C. Linch, B. Vaughan Hudson,
M.H. Bennett, K.A. MacLennan & L. Anderson
British National Lymphoma Investigation, University College
and Middlesex School ofMedicine, London, UK.
Between February 1974 and December 1984 296 patients
with stage III/IV large cell or mixed small and large cell
non-Hodgkin's lymphoma (NHL) were treated initially with
CHOP combination chemotherapy. Seventy-five per cent of
patients were aged 50 years or above. Sixty-three per cent
had stage IV disease, 47% had B symptoms, 43% had an
ESR >40mmh-', 27% had mediastinal involvement, 26%
bone marrow involvement and 36% presented with a low
albumin. The complete remission rate was 49%, the DFS
27% and the overall survival 36% at 5 years. In these
patients who attained a CR the survival was 67% at 5 years
with little evidence as yet of a plateau. The complete remis-
sion rate was dependent on stage being 73%, 41%, 51% and
33% for stages IIIA, IIIB, IVA and IVB respectively. In a
group of 86 patients with stage I/II high grade NHL treated
with CHOP over this period the CR rate was 61% and
overall survival at 5 years 41%. The serum albumin at
presentation was an equally powerful prognostic factor for
the attainment of complete remission as stage IVB patients
with a low albumin having a CR rate of 29%. Age had no
effect on CR rate. Once CR was attained these prognostic
factors became irrelevant. The results of salvage therapy at
all stages were poor. This study indicates that CHOP therapy
will mainly cure one-third of patients with advanced high
grade NHL and in those with IVB disease and a low albumin
the prospects for cure are very low.
Radiotherapy after intensive chemotherapy and autologous
bone marrow transplantation for resistant Hodgkin's disease
A.K. McMillan, J.G. Gribben, J.S. Tobias, D.C. Linch &
A.H. Goldstone
Bloomsbury Transplant Group, University College and
Middlesex Hospital School ofMedicine, London, UK.
Seventy-four patients with resistant Hodgkin's disease were
treated with 'BEAM' chemotherapy and autologous bone
marrow transplantation. The overall actuarial disease-free
survival at 3 years is 62.5%. There were seven procedure
related deaths (9.5%). Of the 65 patients evaluable for
disease at 3 months there were 19 complete responders. These
patients received no further treatment. There have been four
relapses and one late toxic death from pneumonitis in this
group. There was no response in six patients and two of
these died soon after post graft reassessment. Thirty-three
patients obtained a partial response to BEAM. Seventeen
were given subsequent radiotherapy; a full dose mantle was
planned in eleven patients, an inverted Y in four and 'top up'
treatments in a further two patients. Of the 15 full courses
there were two major delays and two reductions in dose
because of myelosuppression. Two patients who received a
mantle developed moderate pneumonitis requiring systemic
steroid therapy. One patient (UPN 337) has received a
sequential full mantle and para-aortic strip with no
significant myelosuppression. Assessment of the response and
progress of the 17 radiotherapy recipients is that four
obtained a CR, although one later relapsed, eight have
remained in stable PR and five have had disease progression.
Twelve out of 17 seem to have responded favourably though
this must be viewed with caution as two patients initially
assessed as PR have obtained a later CR and a further four
patients have had progressive improvement on CT scan over
periods of one to three years without subsequent
radiotherapy. This analysis indicates that radical
radiotherapy post BEAM for Hodgkin's disease is possible in
many patients but that demonstration of its efficacy will be
difficult. It must be emphasised that residual masses on imag-
ing for assessment do not invariably indicate that rapid
disease progression will follow.
The management of primary cerebral lymphoma with initial
chemotherapy
M. Brada, D.P. Dearnaley, A. Horwich & H.J.G. Bloom
Academic Radiotherapy Unit, Royal Marsden Hospital, Sutton
andLondon, UK.
Between 1986 and 1988 10 patients with primary cerebral
lymphoma (PCL) were treated with initial MACOP-B
chemotherapy followed by radiotherapy. All demonstrated
radiological response to chemotherapy but this did not
predict final clinical outcome. The overall median survival
was 13 months. Patients with poor MRC neurological perfor-
mance status (NPS) 2-4 had a median survival of 5 months.
Only two of seven patients with NPS 0-1 died and the
median survival is 18 months with a median follow-up of
seven months (2-32 months). Quantitative sequential
measurement of blood-tumour (BTB) and blood-brain bar-
rier (BBB) with gallium EDTA and PET scanning in two
patients suggests an early repair of BTB after chemotherapy.
The results were compared to 25 patients with PCL treated
between 1963 and 1986 with radiotherapy as the main treat-
ment modality. The overall median survival was 18 months.
Patients presenting with poor NPS (2 and 3) had worse
survival (median survival 8 months) compared to patients
with good NPS (median survival 22 months; P <0.025).
Patients diagnosed and treated from 1982 to 1986 had
significantly worse prognosis when compared to earlier
treated patients. None of the patients were in an 'at risk'
group or had AIDS.
The results of combined modality therapy are not
significantly different when compared to historical series and
we have to await long-term outcome before recommending
combined modality therapy as the treatment of choice.
Studies of BBB and BTB should serve as a basis for future
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Functional outcome following treatment of non-Hodgkin's
lymphoma (NHL) presenting with spinal cord compression
(SCC)
R. Eeles, P. O'Brien & M. Brada
Radiotherapy Unit, Royal Marsden Hospital, Sutton, Surrey,
UK.
Between 1971 and 1988, 20 patients with previously undiag-
nosed NHL presented with extradural SCC. All had
intermediate and high grade NHL (Working Formulation).
They were aged 12-75 (median 55) years. Thirteen had stage
I and II and seven stage III and IV disease. The median
follow-up was 42 months (15-163 months). Three patients
were ambulant, nine paretic and eight paraplegic; 14 were
incontinent of urine and 3 were faecally incontinent.
All patients had decompressive surgery. Mobility improved
in 10 and 11 were fully ambulant. One patient deteriorated.
Fifteen had normal sphincter function.
The first treatment after surgery was chemotherapy in nine
and radiotherapy in 11 patients. Function remained
unchanged in all regardless of the initial therapy. Median
survival of 20 patients was 6 months (1-163 months). The
strongest predictor of survival was mobility after surgery,
even when corrected for age and stage at presentation.
Following surgical decompression, the functional outcome
of patients with SCC due to NHL is not influenced by the
choice of subsequent therapy. The treatment should be ap-
propriate for prognostic factors such as histology, stage and
age. Paraplegia after decompression carries a poor prognosis.
The potential impact of estimated alpha-beta ratios on mantle
technique
D.J. Sebag-Montefiore, E.J. Maher & J. Young
Regional Centrefor Radiotherapy and Oncology, Mount
Vernon Hospital, Northwood, Middlesex, UK.
There is increasing interest in the late complications of
radiotherapy together with awareness of the importance of
dose per fraction, as well as dose. Dosimetry of the mantle
field is complicated by the irregular treatment volume with
varying distances between tumour and normal tissues across
it. Published studies rarely provide sufficient information to
allow estimation of dose and dose per fraction to normal
tissues at risk. This study investigated the effect of variation
in technique between radiotherapy departments.
Eleven superintendant radiographers were questioned
about the 'mantle' technique in their departments. All aimed
to deliver a minimum tumour dose of 30-35 Gy to micro-
scopic and 35-40 Gy to macroscopic disease. None routinely
recorded dose or dose per fraction to all normal tissues at
risk (lung, spinal cord and heart).
There were variations in machine energy, patient position,
points of prescription, shielding and field weighting between
the departments. The techniques were compared in an 'ideal'
patient and potential risks for normal tissue damage
estimated using an alpha-beta ratio of 3 for heart and 1.5
and 3 for spinal cord. Considering the techniques used, there
were variations of 5-30% in estimated biological damage to
thoracic spinal cord and heart.
If useful studies are to investigate different
radiotherapeutic techniques in the treatment of upper half
Hodgkin's disease, dose and dose per fraction to lung, spinal
cord and heart should be formally recorded in addition to
minimum tumour dose.
Poster presentations
Laboratory research
Intraperitoneal activation of lymphocytes by IL-2: initial
haematological and immunological observations
P.D. Allen & M.G. Macey, D.H. Johnson, N.S. Williams &
A.C. Newland
Departments ofHaematology and Surgery, The London
Hospital, Whitechapel, London El JBB, UK.
We have seen generation of lymphokine activated killer
(LAK) activity after intraperitoneal infusion of blood
lyphocytes, obtained by leukopheresis, incubated in vivo with
simultaneously administered doses of recombinant IL-2 (rIL-
2) increasing from 11.5 to 135,000 U kg-' h-' for 10 days.
This was followed by transfer of LAK cells from the
peritoneum by Denver shunt. Mild pyrexia (n = 7), malaise
(n = 7), anorexia and nausea (n = 4) were observed. There
was no evidence of capillary leak syndrome, however, and all
patients developed an early lymphopenia and anaemia which
required transfusion of packed cells in five cases. Platelets
and clotting activity remained normal but an eosinophilia
and neutrophilia were observed. Lymphocyte subset markers
and natural killer activity to K562 targets were studied
serially during the 10-day infusion period by flow cytometric
analysis. A significant increase in NK (CD16 +) and
activated (CD25 +) cells was observed in the peritoneal
cavity and NK cell activity increased in cells from both the
peritoneal cavity (7-33%) and blood (10-15%). Using this
new technique a LAK response may be induced within the
peritoneal cavity and appears to be transfered into the
systemic circulation. It is well tolerated compared to systemic
immunotherapy using in vitro generated LAK and is effective
at lower doses of rIL-2 compared to intravenous administra-
tion.
Cisplatin invoked lead mobilisation studies
R.P. Beaney, E.J. Buxton, A.M. El-Sharkawi, A.C. Todd,
R.A. Braithwaite, L.J. Somervaille, D.R. Chettle, M.C. Scott,
S.J. Jones, I.R. Hainsworth, I. Evetts, W.D. Morgan &
C.J. Evans
University College & Singleton Hospital, Swansea, and
University ofBirmingham and Regional Toxicology
Laboratory, Dudley Road Hospital, Birmingham, UK.
An earlier study of platinum uptake in the kidney following
cisplatin chemotherapy reported, unexpectedly, very high
kidney lead levels in four of 10 subjects, two of whom
definitely had occupational lead exposure, one with excep-
tionally high bone lead, and a third with probable exposure.
This gave rise to the hypothesis that cisplatin could mobilise
lead from the skeleton. We report here two further,
independent, investigations performed at Swansea and Birm-
ingham, the object being to establish if lead mobilisation was170 BRITISH ONCOLOGICAL SOCIETY MEETING
a clinically significant hazard to patients treated with conven-
tional doses of cisplatin. Each centre used a different X-ray
fluorescence system to monitor renal lead levels on a total of
17 subjects (11 male and six female) undergoing cisplatin
chemotherapy for a variety of solid tumours. Whole blood,
serum and urine lead concentrations were also monitored
before and after chemotherapy. In contrast to the earlier
study, none of these subjects was known to be occupationally
exposed. Pre-treatment values of whole blood and urine were
all within their normal ranges for non-occupational exposed
subjects (<30 tg d1-' and 50gSg 24 h- respectively), as were
bone lead levels. Following chemotherapy, renal accumula-
tion of lead was observed in only one subject, who showed
transitory levels up to 100fig Pb g-' kidney tissue, much
lower than the high levels reported previously. This is consis-
tent with the blood, serum and urine analyses which, where
above atomic absorption spectrometry detection limits,
showed only minor changes in all subjects. We conclude that
any lead mobilisation following cisplatin chemotherapy is
unlikely to pose a major hazard to most patients, but that
the possible significance for those exposed to lead and having
high skeletal lead burdens remains to be determined.
Novel epidermal growth factor receptor (EGFR) antibodies:
laboratory selection procedures and clinical potential
C.R. Hamilton, J. Styles & C. Dean
Institute ofCancer Research and Royal Marsden Hospital,
Sutton, Surrey, UK.
Since January 1983, 409/552 patients presenting to the Royal
Marsden Hospital with squamous cell carcinoma of the head
and neck have been staged T any, NO, MO. 344 did not
receive elective nodal irradiation (ENI) and of these 42
(12%) have suffered nodal relapse. As a preliminary to intro-
ducing a novel method of imaging head and neck cancer
patients, and selecting those who might benefit from ENI a
panel of rat monocolonal antibodies has been raised against
the EGFR which is overexpressed in such patients.
Twelve EGFR antibodies have been raised via inoculation
of the Peyer's patch of the rat with a human cell line (HNS)
that over-expresses EGFR. Mesenteric node fusion with the
rat Y3 myeloma cell line gave 12 hybridomas secreting ap-
propriate antibodies.
Initial epitope mapping studies suggest at least three
different binding sites are recognised including that of epi-
dermal growth factor itself.
Scatchard analysis allows determination of antibody
affinity constants (_ 1081 mol-') and ranking of affinity.
Together with the epitope mapping studies appropriate
antibody selection can be made for mouse xenograft work
before final selection for the clinic.
Augmentation of CEA expression in gastrointestinal cancer
with theophylline and interferon
A.J. Jewkes, B. Russell, C. Jones, D. Croom, W.H. Allum &
J. Fielding
Surgical Immunology Unit, Department ofSurgery, Queen
Elizabeth Hospital, Birmingham B15 2TH, UK.
Heterogeneity of CEA expression occurs in most gastro-
intestinal cancers and agents which could render expression.
more homogeneous are likely to increase the efficacy of
antibody related procedures. Increased expression of several
tumour associated antigens has been reported following treat-
ment with theophylline or interferon.
We have therefore investigated the effects of these agents,
in vitro, in four human colorectal cancer lines, a gastric
cancer cell line and fibroblasts. The cell lines chosen cover a
wide range of natural CEA expression. Cellular expression of
CEA was estimated using a monoclonal anti-CEA antibody
and flow cytometry. After 24 h treatment CEA levels were
markedly increased (P <0.001) in two cell lines with
interferon a and in three lines with theophylline. The effect
was dose-dependent. Two cancer lines were unresponsive to
treatment with either agent but both these had high levels of
CEA initially. No CEA expression occurred in fibroblasts.
This effect was then confirmed, in vivo, using xenografts of
the various tumour lines grown subcutaneously in nude mice.
CEA was estimated from whole tumour extracts by radio-
immunoassay and the findings were comparable to in vitro
studies.
Both agents can substantially increase CEA levels in some
cancers cell lines especially those with low inherrent CEA
expression. These drugs may therefore prove useful in im-
proving the diagnosis and treatment of cancers with
antibodies.
Screening for cytotoxic-irradiation interactions in the mouse
lung
S.P. Lockhart, J.D. Down & G.G. Steel
Radiotherapy Research Unit, Institute ofCancer Research,
Sutton, UK.
Irradiation of a 1.9 cm long mouse right hemithorax field
(RHT) to 14 Gy and 18 Gy with 250 kV X-rays produced a
rise in breathing rate which was dose-related and maximal at
14-18 weeks. To investigate the interaction with cytotoxic
drugs, the maximally tolerated dose of cytotoxic drug was
administered intraperitoneally 45 min before 14 Gy RHT
irradiation. Cyclophosphamide 100 mg kg-' accentuated and
accelerated the rise in breathing rate. Ifosfamide 300 mg kg-'
had no such effect. BCNU delayed the rise in breathing rate
to after 26 weeks. Busulphan 30 mg kg-' appeared to abolish
the effect of irradiation, but this was due to the DMSO
vehicle. The following cytotoxics had no effect; doxorubicin
6mg kg-', carboplatin 100mg kg-', vindesine 4mg kg-',
vinblastine 4 mg kg-'.
In conclusion, this is a simple and convenient screening
test for cytotoxic irradiation lung interactions, yielding
qualitative information on the presence of an interaction, and
further information on the time course of the response.
The effect ofhyperthermia on doxorubicin accumulation and
cytotoxicity in a human ovarian carcinoma cell line and its
multidrug resistant variant
E.J. Osborne, S.P.C. Cole & W.J. Mackillop
Department ofOncology, Queen's University, Kingston,
Canada.
The effect of temperature on doxorubicin (ADM) accumula-
tion and cytotoxocity was studied in vitro in the human
ovarian carcinoma cell line A2780-9S and in its multidrug-
resistant variant A2780-AD645. Intracellular ADM levels
were measured by flow cytometry and ADM cytotoxicity was
measured using a clonogenic assay.
ADM cytotoxicity was markedly enhanced in both cell
lines when cells were exposed to the drug at elevated
temperatures. Initial rates of ADM influx were similar in the
two cell lines and both lines showed a similar large increase
in initial rate of influx with increasing temperature. Little
efflux of ADM occurred in the sensitive cell line, but in the
resistant cell line intracellular ADM levels decreased to ap-
proximately 50% of control at 37°C by 20 min. Efflux rates
did not vary with temperature. Studies of the time course of
ADM uptake showed that by 20 min the resistant cells had
markedly lower intracellular ADM levels than the sensitive
cells. Intracellular ADM levels after prolonged exposure toBRITISH ONCOLOGICAL SOCIETY MEETING 171
drugs were significantly increased at elevated temperatures in
both cell lines.
It was concluded that the cytotoxicity of ADM is
enhanced at elevated temperatures in both drug-resistant and
drug-sensitive human ovarian carcinoma cells. The enhanced
cytotoxicity is, in part, due to increased drug accumulation.
The increase in intracellular drug levels is sufficient to explain
the observed thermal enhancement of cytotoxicity in the
A2780-9S cells.
Effect of hypoxia on misonidazole binding in normal and
tumour-bearing mice
M.P. MacManus, A.P. Maxwell & W.P. Abram
Queen's University ofBelfast and Belvoir Park Hospital,
Northern Ireland.
Reductive metabolism of misonidazole (MISO) is enhanced
by hypoxia and produces adducts which bind covalently to
cellular macromolecules. Other workers assert that radio-
active MISO can label hypoxic cells in tumours. We investi-
gated the effect of hypoxia on the distribution of
radiolabelled MISO in normal mice and in mice bearing
CA NT or T50/80 carcinomas. MISO binding was investi-
gated qualitatively by autoradiography and quantitatively by
scintillation counting of solubilised organs or tumours. Mice
were randomised to hypoxic or control groups and injected
i.p. with labelled MISO. Immediately after MISO administra-
tion, mice in the hypoxic group were either exposed to
hypobaric hypoxia (0.5 atmospheres) or given carbon
monoxide i.p., producing >50% HbCO. Mice were killed
24 h after MISO administration, allowing excretion of
unbound drug.
Hypobaric hypoxia increased binding in the T50/80
tumour by a factor of four but binding to CA NT did not
change significantly. Hypobaric hypoxia significantly in-
creased MISO binding to liver (x 2.5), kidney ( x 2.4), heart
( x 1.8) and spleen ( x 2.9) Mice treated with CO also showed
increased MISO binding in these organs. Autoradiographs of
hypoxic liver showed a striking zonal distribution of MISO
binding, suggesting that a steep oxygen tension gradient
exists between portal tracts and hepatic veins. Autoradio-
graphs of hypoxic kidney suggested that the existence of an
oxygen tension gradient between tubules and glomeruli. This
study confirms the value of MISO as a marker for cellular
hypoxia. The demonstration of hepatic and renal oxygen
tension gradients by MISO has not previously been reported.
A new extracellular matrix proteoglycan recognised by a
monoclonal antibody to human embryonal carcinoma
M.D. Mason & M.F. Pera
Institute ofCancer Research, Sutton, Surrey, UK.
Recently the central importance of the extracellular matrix
(ECM) in the control of growth and differentiation has
begun to be appreciated. In particular, the proteoglycan con-
tent of the ECM is known to be of importance, for example
in the attachment of differentiating cells to stromal cells, the
binding of locally released growth factors, and the guiding of
the normal pathway of migration in certain embryonic cells.
We report on a new extracellular matrix proteoglycan
produced by human embryonal carcinoma cells (EC) and
recognised by the monoclonal antibody GCTM-2. Immuno-
histochemistry shows that the antibody stains
undifferentiated stem cells in alcohol and formalin fixed
paraffin sections of human teratomas, and in seminomas. The
epitope is also expressed strongly in fetal muscle, and in
some epithelia, notably gut. An unusual feature of the ECM
proteoglycan in teratoma cells is that the major carbohydrate
is keratan sulphate, formerly thought to be restricted to
cornea and cartilage.
The levels of expression of the antigen fall sharply during
spontaneous differentiation of EC cells in vitro. This is in
marked contrast to the situation in some normal tissues
where highly differentiated tissues have the strongest levels of
expression. An understanding of this phenomenon would
improve our understanding of the control of growth and
differentiation in normal and neoplastic cells.
Determinants ofcellular radiosensitivity. Induction vs repair
T.J. McMillan, A.M. Cassoni, J.J. Eady, S. Edwards,
A. Holmes & J.H. Peacock
Radiotherapy Research Unit, Institute ofCancer Research,
Sutton, Surrey, UK.
The inherent radiosensitivity of cells is likely to be deter-
mined either by the amount of damage that is deposited by
ionising radiation within critical targets in the cell or by the
ability of the cell to repair this damage. In this study we have
examined manifestations of these two processes in order to
determine their relative importance in the determination of
the sensitivity of a range of human tumour cell lines.
Repair capacity has been assessed using a viral reactivation
assay in which cells are infected with irradiated virus and the
ability of the cells to repair the damaged virus is measured by
counting the number of cells containing proliferating virus.
Five cell lines have been examined. Two radioresistant blad-
der carcinoma lines (MGH-U1 and RT112) proved to reac-
tivate the virus to a greater extent than the more sensitive
neuroblastoma lines (HX142 and HX138). However, the
most radioresistant line, HeLA, was least proficient in the
virus assay.
The level of induced DNA double strand breaks has been
measured in nine human tumour cell lines using neutral filter
elution. A broad spectrum of induction curves was found
and it was evident that the level of damage was greater in the
more sensitive cell lines.
We therefore conclude that while no simple relationship
was found between repair capacity and sensitivity the level of
induced damage was modified in line with sensitivity. Thus
the level of induction may be a more significant determinant
of radiosensitivity than repair in human tumour cells.
A comparative study of the accessibility of tumour antigenic
sites in vitro and in vivo
S. Pervez, S.C. Kirkland, A.A. Epenetos, D.J. Evans,
W.J. Mooi & T. Krausz
Departments ofHistopathology and ICRF Oncology Group,
Royal Postgraduate Medical School, Hammersmith Hospital,
London W12OHS, UK.
The clinical usefulness of monoclonal antibodies as carriers
of anti-tumour agents is presently being investigated in diag-
nostic as well as therapeutic fields, but little attention has
been paid to the accessibility of antigenic sites in solid
tumours.
To investigate this problem we used xenograft model
systems of a poorly differentiated and a well differentiated
adenocarcinomas of human large bowel origin. Former of
these employs a cell line (LoVo), in which all tumour cells
express a surface antigen reactive with the mouse monoclonal
antibody AUA1. Tumour xenografts of LoVo (a poorly
differentiated adenocarcinoma) were established in nude
mice, accessibility of tumour cells to injected '25I-AUAI and
its F(ab')2 fragments was investigated. In contrast to in vitro
results, injected '251I-AUAI was localised as detected on
autoradiography, mainly at the peripheal portion of the
tumour on a thin layer of tumour cells (3-5 cells) or adjacent172 BRITISH ONCOLOGICAL SOCIETY MEETING
to the vascularised stroma. On small microscopic sized
tumour islands the antibody penetration was complete. Most
of the radioantibody was found out of the blood vessels onto
the tumour cells indicating adequate permeability of tumour
vasculature for the macromolecules to diffuse out. With
F(ab')2 fragments there was deeper penetration (5-10 cells)
but less radioantibody deposition. The effect of time and
amount of injected antibody on in vivo localisation was
studied. It was demonstrated that at day 6 post-injection
intact antibody showed similar uptake as on days 1 and 3
but in contrast F(ab')2 fragments showed a marked decrease
in tumour uptake at day 6. By increasing the antibody dose
no improvement in antibody penetration was seen. In
another experiment for the first time the binding of in vivo
injected antibody with tumour antigens was very precisely
demonstrated immunohistochemically by biotinylating the
injected antibody AUA1 instead of radiolabelling. In vivo
localisation of antibody was demonstrated on histological
sections of xenografts by incubation with avidin peroxidase.
In the other model, xenografts of a well differentiated
adenocarcinoma cell line (HRA-19) and two monoclonal
antibodies (AUAI and HMFGI) which recognise antigens
present on basolateral and apical membrane domains of
polarised epithelial cells were used. When HRA-19 xenograft
section stained in vitro, AUA1 stained only the basolateral
domains of polarised tumour cells, while HMFG1 stained
only the apical (luminal) domains of tumour cells within
acini. 251I-AUAl injected into nude mice bearing HRA-19
xenografts showed localisation on basally expressed antigen
at the periphery of neoplastic glands, adjacent to the vas-
cularised stroma. In contrast '251I-HMFG1 did not show any
specific localisation as the apical (luminal) antigen recognised
by this antibody was sealed off by junctional complexes
between the cells.
Our study suggests that antibody guided therapy may be
most effective in treating microscopic residual disease of
micrometastases rather than symptomatic large tumours and
that differentiation of the tumour and exact location of
antigen sites are important factors which can affect the in
vivo localisation of antibody.
Predicting response of human tumours to radiotherapy using
short-term culture and the MTT assay
P. Price, T. McMillan, R. Wankling, C. Parkins & A.
Horwich
Radiotherapy Research Unit, Institute of Cancer Research and
Royal Marsden Hospital, Sutton, Surrey, UK.
Human tumour radiosensitivity, as measured by the surviving
fraction at 2 Gy (SF2), has been shown to correlate with
clinical radioresponsiveness. Measurement of SF2 values of
individual tumour biopsies might therefore be useful in
predicting response to radiotherapy. Traditionally SF2 values
are measured using clonogenic assays but a quicker and
simpler assay is required for use in predictive testing. The
MTT assay is a method of quantifying metabolically viable
cells in culture through their ability to reduce tetrazolium to
coloured formazan crystals. The crystals are dissolved and
quantified by measuring optical density (OD). The relation-
ship between OD and cell number is not linear and a calibra-
tion curve for each tumour is used. Using this measurement
of cell number, growth curves of unirradiated and irradiated
cells can be constructed and surviving fraction calculated.
Using five human tumour cell lines a reproducible measure of
survival was obtained and compared well with clonogenic
survival measurements (in parentheses): Hx 171 0.66 (0.69),
Hx156 0.64 (0.62), RTI 120.75 (0.61), MGHUI 0.57 (0.57),
Hx142 0.123 (0.109). The timing of calculating SF2 is deter-
mined by the doubling time of the tumour cells. Four cell
doublings are required to accurately assess 1 log of cell kill.
This is ideal for a predictive assay of human tumour biopsies
grown in short-term culture as SF2 values can be calculated
before fibroblasts overgrow the culture and can be available
to the clinician before treatment. SF2 values have been
obtained from human tumour biopsies grown on plates
coated with a cell attachment matrix (CAM, LifeTrac Inc.).
This forms part of a prospective trial to correlate in vitro
radiosensitivity with clinical radiocurability.
DNA 'fingerprint' changes in patients on combination
chemotherapy
K. Ross, N. Haites, K. Kelly, A. Dawson & B. Bennett
Departments ofMedicine & Therapeutics and Genetics &
Microbiology, University ofAberdeen, Aberdeen, UK.
Hypervariable minisatellite DNA probes 33.6 and 33.15 have
been employed in a novel way in a group of patients receiv-
ing combination chemotherapy in the treatment of lym-
phoma. The multi-locus nature of these probes allows simul-
taneous observation of over 60 different sites in human
genomic DNA, enhancing the possibility of observing
change.
In three patients out of 10 already studied, changes have
been observed in their peripheral leukocyte-derived DNA
fingerprint at some point after starting treatment. Changes
involve both the loss of bands present in pre-treatment sam-
ples and the appearance of novel bands.
Care has been taken to consider possible mechanisms
whereby the changes may have arisen spuriously, or may
represent artefacts generated by the fingerprinting technique.
We conclude that the changes observed are unlikely to repre-
sent any of these mechanisms, and that they may represent
site-specific modification of the DNA by one or more of the
agents used in chemotherapeutic regimes.
We will explore possible mechanisms by which these
changes may have arisen, and discuss possible implications
for risk of therapy-related malignancy
Blood transfusion enhances colonic carcinogenesis in rats -
does indomethacin prevent this?
W.B. Ross, I. Nawroz, M.J. Beavis & J.R. Salaman
CardiffRoyal Infirmary and Western General Hospital,
Edinburgh, UK.
Blood transfusion (BT) can cause immunosuppression and
this may have a detrimental effect on survival and recurrence
for patients with cancer. The mechanisms are unclear, but
may involve increased synthesis of macrophage prostaglandin
E2 and indomethacin may prevent this. Male
Sprague-Dawley rats were given 14 weekly injections of
dimethylhydrazine (16mgkg-'). During week 8 they were
divided into four groups. Group A received no additional
treatment. Group B were given three weekly 1.5 ml trans-
fusions of heparinised blood from DA rats. Group C were
given indomethacin in their drinking water for four weeks
(2 mg kg-' day-'). Group D were transfused with blood as
in group B and given indomethacin to cover this period as in
group C. The rats were killed at 28 weeks and colonic
carcinogenesis assessed histologically: 342 tumours were
identified of which 259 were adenocarcinomas and 83 were
adenomas. The results confirm that BT enhances colonic
carcinogenesis (A versus B: P <0.02, Mann-Whitney test).
This effect may be reversed by indomethacin, but comparison
of groups B and D just failed to demonstrate a statistically
significant difference.
A B C D
Treatment group none BT indomethacin BT +
indomethacin
Colonic tumours 3.3 6.7 4.7 4.7
per rat, mean (17, 1.7) (19, 4.0) (16, 3.5) (18, 2.6)
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The effect of oncogenes H-ras and c-myc on the radiosensitivity
of a mink epithelial cell line
J. Russell & D. Kerr
Departments ofRadiation Oncology and Medical Oncology,
Beatson Oncology Centre, Belvidere Hospital, Glasgow, UK.
We have investigated the effect of the oncogenes H-ras and
c-myc on cellular radiosensitivity. A mink lung epithelial line
was transfected to yield two sublines, H06T1 containing the
H-ras oncogene and MCGMI containing c-myc. At clinically
relevant doses (200 cGy), cells transfected with c-myc showed
a survival (68%) significantly greater than the parent line
(53%). Cells tranfected with H-ras did not show enhanced
survival of this dose. The survival curve for MCGM1 (for
doses in the range 0-1000 cGy) showed a slightly increased
shoulder in the low dose region relative to both CCL-64 and
HOGT1. The width of this shoulder, the Dq, was 180 cGy
for MCGM 1 cells compared to 140 cGy for both GOGT1
and CCL-64. The terminal slope of the survival curve was
slightly steeper for untransfected cells than for the transfected
lines. Expressed as values of Do (the reciprocal of the slope)
HOGT1 had a Do of 230 cGy&and MCGM 1 200 cGy com-
pared to a Do of 200 cGy for CCL-64. These results are
consistent with a modest effect of some oncogenes on cellular
radiosensitivity, especially in the low dose region.
Successful application of a simple chemosensitivity test in the
management of acute myeloid leukaemia
J.M. Sargent, J.K. Wilson, A.W. Elgie & C.G. Taylor
Pembury Hospital, Tunbridge Wells, UK.
We describe a successful application of a rapid semi-
automated colorimetric assay to aid the selection of cytotoxic
drugs for individual patients with AML. Blast cells from
bone marrow were incubated for 48 h with relevant types and
concentrations of cytotoxic drugs. Cell survival after drug
exposure was then calculated using the MTT assay by testing
the ability of the cells to reduce the tetrazolium salt MTT to
formazan. This non-clonogenic approach, measuring the
total cell kill in the entire blast cell population, has been
shown to be equally as valuable as other methods of
chemosensitivity testing.
The amount of formazan produced corresponds to the
number of cells plated. There was variation in drug sen-
sitivity between patients. The assay can be used as a model to
screen resistance modifiers and design combinations of
cytotoxic drugs. Assay results correlated well with the clinical
response after drug administration. Firstly, the attainment of
complete or partial remission corresponded to the clinical
outcome in 90% of cases tested. Secondly, the in vitro res-
ponse paralleled the reduction in the number of blast cells in
the peripheral blood in the 48 h following drug administra-
tion.
This method provides an early prediction of both sen-
sitivity and resistance in individual patients. The repeatability
and speed enables sequential testing throughout the course of
the disease allowing for rapid response to changes in drug
sensitivity.
The clearance of"'1I labelled murine monoclonal antibody from
patient blood by intravenous human antimurine antibody
J.S.W. Stewart, G.B. Sivolapenko, V. Hird, K.A.A. Davis &
A.A. Epenetos
Department ofRadiotherapy, Hammersmith Hospital, Du
Cane Road, London W12 OHS, UK.
Five patients receiving intraperitoneal (i.p.) '3'I labelled
monoclonal antibody for ovarian cancer also received intra-
venous (i.v.) heterologous human anti-murine antibody
(HAMA). It was intended that the i.v. HAMA would in-
crease the catabolism and accelerate the clearance of
absorbed '"'I labelled MAB (thus decreasing the radiation
dose to normal tissue). The pharmacokinetics of '"'I labelled
MAB in these patients was compared with that of 28 other
HAMA negative receiving i.p. radiolabelled MAB for the
first time.
Patients receiving i.v. HAMA demonstrated rapid
clearance of '"'I labelled MAB from their circulation. The
(mean) maximum of '"'I blood content was 11.4% of the
injected activity in patients receiving HAMA compared to
23.3% in patients not given HAMA. Intravenous HAMA
decreased the radiation dose to bone marrow (from 1-131
labelled MAB in the circulation) four-fold. '3'I MAB/HAMA
immune complexes were rapidly transported to the liver fol-
lowing the injection of HAMA. Hepatic antibody
dehalogenation was rapid with 87% of the injected 1311 ex-
creted in 5 days. Despite the efficient hepatic clearance of
immune complexes, dehalogenation of MAB was so rapid,
that the radiation dose to liver parenchyma from circulation
'3', was decreased four-fold rather than increased. There was
no evidence of passive immunisation to HAMA, and all
patients developed homologous two to four weeks after treat-
ment.
The influence of relative timing of carcinogen and operation on
the appearance and distribution of colonic tumours in the rat
model
M. Tilston, A. Abou-Zeid, E. Grant & M.R.B. Keighley
The General Hospital, Birmingham, UK.
Local recurrence of large bowel cancer frequently occurs
adjacent to the site of an intestinal anastomosis, and may be
due to a biological abnormality associated with anastomotic
healing. We have studied the last hypothesis by observing the
yield of tumours at a colonic anastomosis in the DMH rat
polyp/cancer sequence model. One hundred and twenty rats
received a 5 week course of weekly injections of dimethyl-
hydrazine (40 mg kg-') subcutaneously. They were divided
into three surgical groups: left colotomy, partial left colec-
tomy and sham laparotomy, and each group was further
subdivided to receive DMH either 2 weeks before or two
weeks after their laparotomy. All groups were sacrificed 25
weeks after commencement of the DMH course. Tumour
counts were taken either at, or away from the anastomotic
site (see Table).
Colonic operation increased the percentage of rats
developing tumours. A high yield of tumours was observed
adjacent to a colonic anastomosis, especially when a healing
suture was challenged by exposure to a carcinogen.
Laparotomy Colectomy Colotomy
Preop. Postop. Preop. Postop. Preop. Postop.
% rats with tumours 30% 25% 75%* 75%* 80%* 85%*
Anastomotic tumours 1 0 11 16 23 17
Rest of colon 7 5 14 7 8 18
Total 8 5 25 23 31 35
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Photodynamic therapy using polychromatic light for the growth
inhibition ofmulticellular tumour spheroids
M. Turkish, P. Durdey, M.F. Grahn, L. Ilincic,
J.T. Allardice & N.S. Williams
Surgical Unit, London Hospital, Whitechapel, London El, UK.
Photodynamic therapy (PDT) is receiving increasing atten-
tion as a treatment for malignant disease. The cost and
maintenance of lasers is, however, prohibitive and this may
restrict the use of PDT in patients who are otherwise
suitable. We have therefore investigated alternative non-
coherent light sources to determine whether a comparable
cytotoxic effect can be achieved over similar time periods and
irradiation doses. Red and green laser light were compared to
theatre lights and daylight tungsten lamps. Multicellular
tumour spheroids (MTS) from the cell line HRT18 were
pre-treated with 10 lag ml-' of haematoporphyrin derivative
and the cytotoxic effect of different light sources was
measured using tritiated thymidine incorporation. Results are
expressed as mean (± s.e.m.) percentage inhibition.
Irradiance (Jcm-2) % inhibition
Red laser light 10 54.7 (+ 6)a.b
Theatre lights 10 87.0 (± 3.7)a
Tungsten daylight lamps 4.25 70.4 (± 61)b
a.bp <0.01 (ANOVA).
For a given irradiance, growth inhibition of MTS was
significantly greater with a polychromatic light source than
laser light. Polychromatic light may not achieve as effective
tissue penetration as does red light. However, for the
ablation of superficial tumours and adjuvant treatment of the
tumour bed peroperatively, the cheaper alternative of an
adapted polychromatic light source may allow more
widespread use in clinical practice.
Sarcomas and miscellaneous
The application of printed circuit technology to produce a
multichannel probe to measure oxygen
A.E. Brewster, I.C.M. Paterson, J.L. Moore, P. Waller &
R.S. Pickard
Velindre Hospital, Cardifand University of Wales College of
Cardif, UK.
Data about hypoxia fractions in human tumours is circum-
stantial because of the limitations of current methods for
measuring oxygen. A prototype printed circuit was designed
with the dual intention of establishing whether: (1) the
materials and fabrication techniques required were biocom-
patible and (2) such a circuit would be capable of measuring
a biologically generated potential.
The circuit, etched on glass so that the growing cells could
be visualised, was designed with 52 electrodes, 4 x 4 jim size.
They were arranged in quadrants 20 jim apart to correspond
with the approximate size of tumour cells in culture. Three
cell lines, Chinese hamster ovary, a mouse fibroblast and a
mouse neuroblastoma line will grow normally on the circuits
as demonstrated by standard growth curves. S.e.m.s will be
presented showing the complexity of the cell/sensor interface.
To test the circuit's ability to pick up a biologically
generated signal frog cardiac muscle which was visibly con-
tracting was placed onto the circuit. Cardiac potentials were
recorded from each terminal providing data from which the
signal/noise ratio could be calculated.
We have therefore integrated 21 oxygen sensors and three
thermistors into the circuit to measure oxygen in vitro and
have designed a multichannel silicon probe for in vivo use.
This probe will be implanted into a growing tumour to build
up a dynamic three dimensional blueprint of oxygen and
temperature.
Topical 5-fluorouracil in cutaneous AIDS-related Kaposi's
sarcoma
A.M. Brunt, A.G. Goodman & R.H. Phillips
Radiotherapy Dept, St Stephens and Westminster Hospitals,
London, UK.
Five per cent 5-fluorouracil cream (Efudix) is used to treat
selected neoplastic and pre-neoplastic cutaneous lesions. A
frequent indication for treating cutaneous AIDS-related
Kaposi's sarcoma is for cosmesis. Localised lesions are often
treated by radiotherapy or by intralesional cytotoxic
chemotherapy. The self application of a cream to treat early
cosmetically unacceptable sites of disease would be an attrac-
tive therapy for this group of highly motivated patients. We
are conducting a pilot study of 5% 5-fluorouracil cream in
patients with AIDS-related Kaposi's sarcoma. All patients
have two similar early lesions identified and randomly
allocated to treatment with the cream or assessment as the
control. The cream is applied once daily for 1 month, and
then twice daily until 3 months, unless ulceration occurs
before this time. Ten patients have been recruited. Three are
still applying the cream after 6, 6 and 8 weeks with no
response to date. Three patients completed 3 months treat-
ment, two achieving partial responses maintained at 1 month.
Four patients did not complete 3 months application. One
patient died at 3 weeks, two stopped due to intercurrent
opportunistic infection after 6 and 4 weeks, the other patient
admitted poor compliance. The patient who stopped at 4
weeks exhibits a partial response maintained at 2 months.
Erythema was observed in no patient. Further study of this
convenient treatment is recommended to determine whether
it has a role in the management of AIDS-related Kaposi's
sarcoma.
The effect of radiotherapy on local recurrence in Ewing's
sarcoma of bone
N.G. Burnet & C.L. Harmer
Royal Marsden Hospital, London SW3, UK.
To assess local control, 82 cases of Ewing's sarcoma of bone
treated between 1967 and 1986 were reviewed. Forty-four
males and 38 females were treated, median age 16 years.
Thirty tumours arose in the leg, 15 in the arm, 16 in the
pelvis and 21 elsewhere. Size could not be accurately assessed
retrospectively. Sixty-two (76%) have relapsed, median time
to relapse 12 months. Of the 20 (24%) disease-free, two died
from complications of chemotherapy; median follow-up was
40 months but two patients had follow-up of less than 12
months. In addition to the 20 relapse-free patients, 38
relapsed distantly but with local control. Fifty-eight patients
(71%) thus achieved local control. Eleven patients suffered
local relapse alone, 13 local and distant relapse together.
Most patients received both radio- and chemotherapy. Eleven
patients received no radiotherapy, 10 no chemotherapy, and
one received neither. Eleven patients had surgery, eight nar-
row excision and three wide clearance by amputation.
Proximal or distal location in a limb had no effect on
relapse-free rates, which were similar (27%) for all areas
except the pelvis, where only two of 16 (13%) were disease-
free and both died from treatment complications. Four
disease-free patients, including the two who died, had distant
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after first relapse. More patients treated after 1976 remain
disease-free (30%:9%). Fewer local recurrences were seen
with radiation doses of 1,572 ret or more (equivalent to
50 Gy in 25 daily fractions), but there was little or no gain
from higher doses.
Chemotherapy-induced aortic damage
I.J. Neilly, M.A. Ratcliffe, J. Rawles, A.A. Dawson &
B. Bennett
Department ofMedicine, University ofAberdeen and Aberdeen
Royal Infirmary.
Cytotoxic chemotherapeutic agents, particularly the
anthracyclines, are known to be cardiotoxic, but toxic effects
on the aorta have not previously been documented.
In this study diameters of ascending and descending
thoracic aorta were measured by computerised tomography
in 69 patients with lymphoma before and after first line
treatment with one of seven different regimes.
Minor increases in aortic diameter over the period were
expected due to the ageing process. These increases were
greatly exceeded in both ascending and descending aorta
after chemotherapy witdh CHOP and CVP regimes. Smaller
changes, or changes which were not statistically significant,
were noted after MVPP, ChlVPP, ChlVP, mediastinal
radiotherapy and radiotherapy plus MVPP.
Cardiovascular damage associated with certain forms of
cytotoxic therapy is not confined to the heart but also affects
the aorta. This damage to the aorta may clearly be of clinical
importance in the older patients receiving chemotherapy.
This is illustrated by reference to patients, requiring aortic
surgery during or shortly after chemotherapy.
Differential inhibition of tumour and ephiphyseal growth seen
in two cases of osteosarcoma of femur
J.A.S. Pringle, H.B.S. Kemp, R.L. Souhami & J. Pritchard
London Supra-regional Bone Tumour Service, London, UK.
Two males, aged 4 and 11 respectively, presented with
osteosarcoma of the distal femur, with quite extensive
involvement of the femoral shaft. Both were treated with
prospective chemotherapy, resection of the whole femur and
replacement by a growing endoprothesis. Good tumour re-
sponse to chemotherapy was seen in both cases. Evidence of
continued epiphyseal growth during chemotherapy was noted
in gross specimen, fine detail X-ray and histological sections.
A case-control study ofleukaemia and lymphoma in young
persons resident in West Cumbria
M.J. Gardner, M.P. Snee, A.J. Hall, S. Downes, C.A. Powell
& J.D.T. Terrell
MRC Environmental Epidemiology Unit, University of
Southampton and West Cumbria Health Authority,
Whitehaven, Cumbria, UK.
Several studies have shown increases in the incidence of
leukaemia in young persons living close to British nuclear
installations. However, no link has been established between
the occurrence of such cases of leukaemia and the operation
of any of the nuclear plants.
The West Cumbria case-control study seeks to examine
whether the increased incidence of lymphoid malignancy,
seen in part of the area, can be explained on the basis of
increased prevalence of known risk factors, or alternatively
establish that the observed cases of malignancy are due, in
part, to the activities of the largest nuclear site in the
country: Sellafield. Some 97 cases of leukaemia and lym-
phoma, diagnosed in a 35-year period from 1950, in West
Cumbria have been compared with 1,001 age and sex
matched controls. Putative risk factors that may have
resulted in enhanced irradiation from the Sellafield nuclides,
such as place of birth, consumption of seafood and beach
activity have been examined.
A particular feature of the study is the examination of
paternal radiation exposure as a possible aetiological factor;
the particulars of all study subjects have been cross-linked
with the occupational records of persons who have ever
worked at the plant. BNFL have supplied us with radiation
dosimetry for linked individuals.
The preliminary results of the study will be discussed.
Are you being served? British Oncology Data Managers'
Association (BODMA)
T. Young (on behalf of the BODMA committee)
Meyerstein Institute ofRadiotherapy & Oncology, Middlesex
Hospital, London, UK.
BODMA was founded in December 1987 to represent oncol-
ogy data managers and clinical trial co-ordinators in the UK
and to organise national meetings and regional workshops. A
recent CRC report recommended that a training programme
and career structure should be established.
Although some data managers now work in units funded
by the CRC and MRC dedicated to conducting clinical
studies, many still work alone. One of the association's first
aims is therefore to identify and contact all data managers.
Current membership is 116: Scotland and NE 22, Manchester
and NW 11, Yorkshire 6, Midlands 19, Plymouth 2, London
56. Wales and East Midlands are poorly represented.
The Scottish region organised the first national meeting in
Glasgow last autumn. Topics covered included basic cancer
pathology, statistics, protocol and form design, computer
software packages and the Data Protection Act. The London
and SE region has drawn up a questionnaire to provide
baseline information on job descriptions, responsibilities and
experience which will be used when planning future meetings.
Results from this survey should be available for presentation
soon. Information on disease sites of interest and computing
facilities could be used for collaboration between centres. The
association is co-operating with the EORTC Data Managers'
Group and learning from European experience.
Clinical studies are important. More efficient use of data
managers would help to optimise clinical research, locally,
nationally and internationally.
Breast cancer
Effervescent oral APD treatment of bone metastases from
breast cancer
R.E. Coleman, P.J. Woll & R.D. Rubens
ICRF Clinical Oncology Unit, Guy's Hospital, London, UK.
The bisphosphonate APD (Pamidronate) is a potent inhibitor
of osteolysis and the most effective agent for the treatment of
hypercalcaemia of malignancy. Long-term inhibition of bone
destruction is possible with repeated intravenous administra-
tion and this may reduce pain and promote bone healing. In
the past the use of oral APD has been limited by upper GI
intolerance due to the drug's corrosive properties. We have
tested a novel effervescent formulation of oral APD (pro-
vided by Ciba-Geigy Pharmaceuticals).
Thirteen patients with bone metastases from breast cancer
were studied, eleven with evidence of increased osteolysis
(urinary calcium excretion > 0.4 mmol mmol-' creatinine).176 BRITISH ONCOLOGICAL SOCIETY MEETING
The first four patients were treated with 150 mg daily for 4
weeks. Subsequent cohorts of four patients received 300 mg
and 450 mg daily. Dose escalation within patients was
allowed only after completion of four weeks treatment at a
constant dose. APD was tolerated without toxicity up to a
dose of 450 mg a day. In two pts dose escalation to 600 mg
a day resulted in unacceptable nausea, vomiting and indiges-
tion. All patients showed a fall in urinary calcium excretion
to normal indicating adequate absorption of APD and
inhibition of bone resorption at all dosages. Serum calcium
fell significantly but remained within the normal range.
Effervescent oral APD inhibited bone resorption secondary
to breast cancer at doses which were non-toxic. Studies of
long-term tolerance of oral APD and its use as an adjunct to
systemic treatment are now indicated.
In vivo localised 31P spectroscopy ofhuman breast carcinoma
J. Glaholm, J.C. Sharp, D. Collins, N.P. Rowell,
M.O. Leach, K. Farnsworth, V.R. McCready & A.J. Hind
Nuclear Magnetic Resonance Unit, Royal Marsden Hospital,
Sutton and Siemens Ltd, Sunbury-on-Thames, UK.
In vivo 31p MRS provides a non-invasive measurement of
cellular phosphorous metabolism. Eight patients with locally
advanced breast carcinoma hve been assessed during treat-
ment. Phosphomonoesters (PME) and phosphodiesters
(PDE) (precursors and degradation products of phospholipid
metabolism respectively) were prominent in all of the
tumours. The technique may therefore provide an indirect
indicator of cell membrane synthesis and hence replication.
Phosphocreatine (PCr), which provides a reserve of high
energy phosphate, was undetectable or at a low level in all of
the tumours examined. Adenosine triphosphate (ATP) and
inoganic phosphate (Pi) were readily detected in all cases
providing an indication of the efficiency of cellular
bioenergetic metabolism.
Five patients were treated with combination
chemotherapy, two with tamoxifen and one with external
beam irradiation. Three patients responding to chemotherapy
demonstrated spectral changes, predominantly reduction of
the PME and PDE peaks, bioenergetic changes (ATP, Pi,
PCr) were less consistent. In two patients these changes
preceded the clinical response. No spectral changes were
observed in the remaining two non-responding patients. One
of the tamoxifen treated patients showed neither spectral nor
clinical response to therapy. The second demonstrated a
generalised increase of the NMR signal two weeks after
commencing tamoxifen with concomitant increase in tumour
blood flow as measured by 99Tcm labelled HMPAO. These
changes preceded an increase in the tumour volume and were
therefore early markers of disease progression. No spectral
changes were observed during treatment in the patient under-
going radical external beam breast irradiation, despite a
reduction of tumour volume.
In conclusion we have observed spectral changes which
preceded clinically measurable changes in tumour volume. In
vivo 31P NMR spectroscopy may therefore provide a sensitive
non-invasive method for assessing therapeutic response in the
treatment of breast cancer.
How far do staging investigations in breast cancer aid the
clinician?
R. Glynne-Jones, A. Ahmed, T. Young & P.J. Ell
Meyerstein Institute ofRadiotherapy and Institute ofNuclear
Medicine, University and Middlesex School ofMedicine,
London, UK.
This retrospective study aimed to assess the clinical import-
ance of current staging procedures in breast cancer. The
analysis comprises a 10-year cohort of all 398 women who
presented to a single unit between 1978 and 1987, with
clinically staged I-III breast cancer. Routine screening for
metastases yielded 72/389 'Tcm bone scans, 13/386 chest
radiographs and 21/271 liver ultrasound scans, which were
retrospectively classified by their original report as
equivocally or definitely indicative of metastases. In addition,
13/347 serum alkaline phosphatase levels were elevated
beyond the normal range of the institutions concerned.
Further history, advancing disease, local radiographs or a
repreat scan gave information which reduced the overall rate
of detection of metastatic disease at three months to 29/389
(7%) bone scans, 10/386 (2.6%) for chest radiographs, 8/271
(3%) for liver ultrasound and 3/347 (1%) for serum alkaline
phosphatase.
The risk ofoccult invasive cancer of the breast following
excision biopsy showing in situ ductal carcinoma ofcomedo
pattern
P.D.J. Hardman & A. Worth
The Cancer Control Agency ofBritish Columbia, Vancouver,
BC, Canada.
During the period I January 1985 to 31 August 1987, 62
cases of in situ ductal carcinoma of predominant comedo
pattern were diagnosed in British Columbia, following
excision biopsy for a palpable or mammographically demon-
strable lesion of the breast. The excision biopsies were each
performed with the intention of removing the lesion com-
pletely. Fifty-seven (92%) underwent subsequent wide re-
excision or total mastectomy, usually within one calendar
month of the excision biopsy. Occult invasive disease was
demonstrated in 14 of the subsequent wider excision speci-
mens (24.5%) and residual in situ carcinoma was present in a
further 24 (42.1%) cases. Therefore, the total incidence of
residual disease was 66.6%.
Axillary lymph node sampling was performed in 54 cases.
Lymph node metastases were observed in two cases (3.7%)
and were each associated with occult infiltrating ductal car-
cinoma in the breast.
This suggests that in situ ductal carcinoma of predominant
comedo pattern may be more widespread and associated with
a higher incidence of invasive ductal carcinoma than
previously accepted.
Adjuvant chemotherapy for breast cancer: what is the cost?
R. Kalra, A.C. Jones, M. Greenall & K.R. Durrant
Departments ofRadiotherapy and Surgery, Churchill Hospital,
Oxford, UK.
An overview has demonstrated a significant difference in
survival for adjuvant chemotherapy in women under the age
of 50. However, there may be a considerable cost for this
improvement in terms of patient side effects and financial
resources. A study was initiated to assess the toxicity and
quality of life associated with adjuvant chemotherapy.
Between January 1986 and December 1988, 69
premenopausal patients were treated by simple mastectomy
or local wide excision and axillary node sampling followed by
six cycles of CMF chemotherapy (Cyclophosphamide
400 mg m2, Methotrexate 40 mg m-2 and 5-fluorouracil
600 mg m-2 i.v. days 1 and 8). Axillary + chest wall or breast
irradiation was given after the second cycle ofchemotherapy.
Fifty-five patients have completed treatment and are
evaluable.
Most patients experienced nausea and vomiting; in the
majority anti emetics were ineffective. Hair loss was usually
mild and only three patients required a wig. Anxiety and
depression were reported by 32 patients.BRITISH ONCOLOGICAL SOCIETY MEETING 177
Thirty-five patients were unable to complete six cycles of
chemotherapy. This was due to neutropenia in 13 patients
and 12 patients refused to continue chemotherapy after a
mean of three and a half cycles.
The reduction in mortality for adjuvant chemotherapy is
associated with unpleasant side-effects. A major priority must
be the reduction in the toxicity of this otherwise valuable
treatment.
Efficacy and toxicity of single agent chemotherapy in advanced
breast carcinoma
P.A. Lawton, M.J. Ostrowski, T. Young & M.F. Spittle
The Middlesex Hospital, London, UK.
In 1985 the Multicentre Cancer Chemotherapy Group com-
menced a randomised study to compare doxorubicin
(70 mg m-2), epirubicin (70 mg m-2) and mitozantrone
(14 mg m-2) as single agents in patients with metastatic
breast carcinoma. The patients had received no previous
chemotherapy for their metastatic disease. Eighty-eight
patients were entered and 87 were evaluable. The survival of
all the patients was 32% at 1 year and 9% at 2 years with no
significant difference in the three groups. The response rates
were 40% (10 of 28 patients) with doxorubicin, 36% (nine of
28 patients) with epirubicin and 26% (eight of 31 patients)
with mitozantrone but these differences did not reach statis-
tical significance. Using WHO scores, 21% of patients with
doxorubicin and 20% with epirubicin had grade 3 nausea/
vomiting as their worst score compared with none with
mitozantrone. However, 32% of the patients treated with
mitozantrone did have grade 2 nausea/vomiting. WHO scores
for alopecia were grade 3 for 57% of the patients dox-
orubicin compared with 31% with epirubicin and 3% with
mitozantrone. Myelosuppression and infective episodes
occurred more frequently in the patients receiving mitozan-
trone (14% of the total courses of mitozantrone were delayed
due to neutropenia compared with only 7% for doxorubicin
and 3% for epirubicin). Two cardiac complications were
reported (angina in one patient on doxorubicin and a cardio-
myopathy in one patient after 10 courses of epirubicin). This
study shows that the low efficacy and toxicity of all three
agents limit their use as single agents in advanced breast
carcinoma and in the case of mitozantrone improved patient
tolerance may be balanced by an increased risk of myelosup-
pression.
Treatment of advanced poor-prognosis breast cancer in young
women with doxorubicin plus ifosfamide/mesna
M.J. Millward & B.M.J. Cantwell
Department ofClinical Oncology, University ofNewcastle
upon Tyne, Newcastle upon Tyne, UK.
Younger women with advanced breast cancer frequently
present with poor prognostic features such as visceral disease
and inflammatory local recurrences. We have treated 20 such
patients (pts) aged < 50 years (mean age 42 years) who had
not received chemotherapy (16 pts) or had progressive disease
on mitoxantrone (four pts). To give high doses of alkylating
drugs with the standard most active single agent (doxo-
rubicin) we combined 40 mg m-2 bolus followed by ifos-
famide 5 mg m-2 over 24 h with concomitant mesna. Starting
doses were reduced in five pts because of previous
radiotherapy, poor performance status or advanced liver
involvement. Cycles are repeated every 3 weeks to a maxi-
mum of 4. Results are; CR four pts, PR eight pts, SD
threepts, PD two pts, too early three pts, overall response
rate 71%. Responses have been seen in local recurrence,
liver, lung and pleural disease and in patients resistant to
mitoxantrone. The median duration of response is 7 months.
Eight relapsed or non-responding patients have received sal-
vage chemotherapy with mitomycin-C and vincristine with
two responses. The overall median survival is 12 months.
WHO grade 3 myelosuppression occurred in five pts but no
infectious complications have been seen. Falling creatinine
clearance has lead to discontinuation of ifosfamide in
two pts. One episode of haemorrhagic cystitis occurred after
four cycles of therapy. Doxorubicin/ifosfamide is a highly
active regimen in these young, poor prognosis patients and
the high degree of antitumour activity may be explained by
tumour kinetic parameters, but intrinsic drug resistance re-
mains a problem and long-term survival is poor. The incor-
poration of these drugs in an alternating schedule with a
mitomycin-C based regimen appears worthy of investigation.
Radiation-induced brachial plexus injury: follow-up of two
different fractionation schedules
S. Powell & J. Cooke
Royal Marsden Hospital, London, UK.
All 449 breast cancer patients treated with postoperative
radiotherapy to the breast and lymph nodes between 1982
and 1984 have been followed for 4-6 years. In this group
two different fractionation schedules were used, one five
times a fortnight and one daily, both over 6 weeks. The
calculated dose to the brachial plexus was 45 Gy in 15 frac-
tions or 54 Gy in 30 fractions. These schedules are equivalent
doses using the NSD formula. The diagnosis of a brachial
plexus injury was made clinically and computed tomography
was used to distinguish radiation injury from recurrent
disease.
The actuarial incidence of a radiation induced brachial
plexus injury for the whole group was 4.9% at 6 years. No
cases were seen in the first 10 months following radiotherapy.
The incidence rises between 1 and 4 years and then starts to
plateau. When the large fraction size group is compared with
the small fraction size group the incidence at 6 years is 5.9%
and 1.0% respectively (P <0.1). Two different treatment
techniques were used in this group but were not found to
contribute to the probability of developing plexus injury.
It is concluded that radiation using large doses per fraction
are less well tolerated by the brachial plexus than small doses
per fraction, and a commonly used fractionation schedule
such as 45 Gy in 15 fractions may give unacceptably high
brachial plexus morbidity. The use of small doses per frac-
tion or avoiding lymphatic irradiation is advocated.
Genito-urinary and gynaecological cancer
Bleomycin, ifosfamide and cisplatin (BIP) in cervical cancer:
results in 100 cases
E.J. Buxton, G. Blackledge, J.J. Mould, J.S. Tobias,
J. Monaghan, D. Spooner, A.D. Chetiyawardana & A. Slater
West Midlands Cancer Research Campaign Clinical Trials
Unit, Birmingham, University College Hospital, London and
Queen Elizabeth Hospital, Gateshead, UK.
Patients with recurrent, advanced and early stage but high
risk/node positive carcinoma of the cervix have an
unfavourable prognosis. Systemic therapy may improve prog-178 BRITISH ONCOLOGICAL SOCIETY MEETING
nosis as neoadjuvant, cytoreductive or adjuvant therapy in
primary disease. For maximum benefit systemic therapy
should have high activity. We have treated 100 patients with
BIP. Fifty patients with recurrent inoperable disease entered
a phase II study of this combination. Fifty patients with
primary inoperable disease also received BIP as cytoreductive
therapy prior to radical local radiotherapy. Patients were
treated with B 30 mg infused over 24 h, followed by
P 50 mg m-2 bolus and I 5 g m-2 infused over 24 h, with
concomitant hydration (total 8 litres in 3 days). Mesna
8 g m-2 was given as a systemic uroprotector during and for
12 h following I. At least two cycles were given unless there
was disease progression with a maximum in responding
patients of six cycles in the recurrent group and three cycles
in the primary group.
Seventy of 99 patients (71%) responded (95% CI
62-80%). In the recurrent disease group 34/49 patients
(69%) showed objective response with 10 complete responses
(22%). Median response duration was 8.4 months. All
patients experienced alopecia, and nausea and vomiting.
Blood transfusion was required in 23% of cycles. WHO
grade 3/4 infection occurred in 5% of courses. Grade 3/4
CNS toxicity was seen in 7% of courses. Two patients
developed grade 3/4 renal toxicity. In the neoadjuvant group
36/50 patients (72%) showed significant tumour regression.
Only three patients showed disease progression during
chemotherapy and these had progression during subsequent
radical radiotherapy. There was no evidence of enhanced
acute radiotherapy toxicity.
BIP is highly active in cervix cancer and may be used for
effective cytoreduction in around 70% of patients. The role
of BIP as cytoreductive therapy before radical radiotherapy
in primary inoperable disease is currently being tested in a
multicentre randomised trial. Eighty patients have entered
this study. The regimen also has potential as adjuvant
therapy in early stage 'high risk' disease. We have initiated a
prospective randomised trial testing the role of BIP as
adjuvant therapy in patients with positive nodes at radical
hysterectomy.
Staging of prostatic cancer: MRI, CT and transrectal
ultrasound experience
M. Cobby, D. Gillat, J. Browning & E. Whipp
Bristol Radiotherapy Centre and Bristol Royal Infirmary,
Bristol, UK.
Many patients with prostatic carcinoma will present when
metastatic spread has already occurred. However, it is often
diagnosed incidently following transurethral resection for
outflow obstruction when the disease may be confined to the
gland. These patients are suitable for possible curative
treatments such as radioactive seed implants or radical prost-
atectomy. For these to be considered accurate preoperative
staging is required.
Using a variety of techniques we have staged a series of
100 patients with histologically proven prostatic carcinoma.
In 25 patients endorectal ultrasound was compared with
examination under anaesthesia and fine needle biopsy where
appropriate, before the insertion of 125I seeds. Comparison
was made with clinical examination and, where possible, with
endorectally guided biopsy or surgically excised specimens in
the remaining patients, 50 of whom underwent endorectal
ultrasound and 25 a combination of endorectal ultrasound
and magnetic resonance imaging. Computed tomography was
performed on a number of patients from each group.
Transrectal ultrasound was accurate in assessing capsular
breach and this was identified more frequently than by MRI.
However, MRI more clearly showed the full extent of local
invasion and was better at examining the bladder base. It
also revealed lymphadenopathy and unsuspected pelvic bony
metastasis in a number of patients.
Preoperative assessment ofmyometrial invasion by vaginal
endosonography
D.J. Cruickshank, J.M. Randall & I.D. Miller
University ofAberdeen Medical School, Foresterhill, Aberdeen,
UK.
Endometrial cancer is the most common gynaecological
malignancy and over the last 20 years there have been no
improvements in the cure rate. Of the major prognostic
factors in endometrial cancer only clinical stage histological
tumour type and degree of differentiation are available
preoperatively. More accurate preoperative staging, together
with an assessment of myometrial invasion, cervical involve-
ment and possibly adnexal spread would have the potential
to improve management in endometrial cancer. In this pilot
study preoperative transvaginal endosonographic assessment
of myometrial invasion was compared with histological
measurement in five consecutive patients with endometrial
neoplasia. Preoperative ultrasound findings and postoperative
microscopic assessment were in good agreement. Departure
from the 'gold standard' of microscopic assessment was
much less for vaginal ultrasound (- 21% to + 6%) than for
macroscopic assessment (- 86% to + 18%). Selective
therapy based on preoperative information on available
prognostic factors would be expected to improve the results
of treatment but perhaps more importantly minimise the
morbidity and mortality by permitting conservative but
effective surgery in this group of patients who tend to be
elderly, obese and unfit.
The cost effectiveness of serum CA125 monitoring in epithelial
ovarian cancer
D.J. Cruickshank & J. Cairns
Aberdeen University, Aberdeen, UK.
The aim of this study is to evaluate whether the improved
information derived from the use of CA125 in monitoring
ovarian cancer has value in excess of its cost. A conventional
monitoring scenario utilising ultrasound is compared with
two new management scenarios, one where CA125 supple-
ments the use of ultrasound and another where CA125 is
used instead of conventional monitoring. Data from the
literature on sensitivity, specificity and predictive value of the
different means of assessing response is used to provide
illustrative costs and benefits. The demonstration of a lead
time and the superior sensitivity of CA125 monitoring over
clinical assessment of response in studies of second look
surgery suggest that serial CA125 measurement is applicable
in non-evaluable disease (60%). Unnecessary second look
surgery could be avoided and the earlier detection of progres-
sive disease indicating ineffective chemotherapy would yield
benefits by a reduction in the number of pulses of
chemotherapy saving the health service resources and reduc-
ing morbidity associated with chemotherapy. At best, the
response rate in advanced ovarian cancer is 74%. At least
26% of patients therefore receive chemotherapy unneces-
sarily. The earlier detection of recurrence after surgery with
CA125 in patients with early stage disease not previously
treated might be expected to improve survival.
Immunoscintigraphy ofovarian carcinoma
B. Haylock, T. Maughan, M. Hayward, P. Facey,
M. Shelley, R. Fish & M. Adams
South Wales Radiotherapy and Oncology Service, Velindre
Hospital, Cardif, UK.
CA-125 is a membrane antigen detected in tumour sections
and serum from the majority of patients (pts) with adenocar-BRITISH ONCOLOGICAL SOCIETY MEETING 179
cinoma of the ovary. We have attempted to use a
radioiodinated anti-CA125 monoclonal antibody, OC-125, to
image ovarian tumours using immunoscintigraphy and com-
pare the findings with clinical examination and existing
radiological techniques.
Thirteen scans were performed in 11 pts with FIGO stage
III A-C and IV ovarian adenocarcinoma. At the time of
scanning 11 pts had residual macroscopic disease (eight pts
<2 cm, three pts > 2 cm). One hundred and eleven MBq of
"3'I OC-125 was given i.v. 4 days before scanning with an
IGE 400 T camera (EL-Scintapex 009 data processor) Sub-
traction films were obtained using TcO4 in a dual isotope
technique.
Clinical examination was positive in 3/11 pts with disease.
Ultrasound scanning yielded 3/10 true positive and 2/10
equivocal results. CT scanning showed true positive in 5/11
cases and 5/11 equivocal results. Considering pelvic and
peritoneal sites separately, immunoscintigraphy gave 9/13
true positive, 4/13 false negative and 2/2 true negative results.
Serum CA-125 levels were elevated (>35 units ml-') in
88% pts with macroscopic residual tumour.
This pilot study suggests that immunoscintigraphy will
recognise residual tumour when clinical examination and
other radiological investigations fail.
Neoadjuvant chemotherapy before radical radiotherapy for
transitional cell carcinoma of the bladder
G.C.W. Howard, M.A. Cornbleet, T.B. Hargreave &
G. Chisholm
Department ofClinical Oncology and Department of Urology,
Western General Hospital, Edinburgh, UK.
The objective of this ongoing study is to assess the feasibility
and toxicity of neoadjuvant chemotherapy before radical
radiotherapy for transitional cell carcinoma of the urinary
bladder. We specifically wish to assess whether by giving
chemotherapy first we compromise the ability to give radical
radiation; delay the palliation of distressing symptoms; or
allow progression of tumour.
Patients considered suitable have been those with clinically
T3 or T4 histologically proven transitional cell carcinoma of
the bladder. Such patients have received three courses of
chemotherapy with methotrexate (200 mg m-2 i.v. with
folinic acid rescue) plus cisplatin (100 mg m2), the dose of
these being adjusted in the presence of poor renal function.
Radical radiotherapy (52.5 Gy in 20 fractions in 26 days,
three field plan) is then started after full restaging. Further
full assessments of toxicity and tumour response are per-
formed I and 6 months after the completion of treatments.
To date 13 patients have been treated in this way. We have
found the chemotherapy to be extremely well tolerated but
that reductions in the dose of the drugs have been necessary
in the majority of courses. We have not found it necessary to
adjust the standard radiotherapy as a result of prior
chemotherapy. In all patients with symptoms there has been
a symptomatic response during chemotherapy and we con-
clude that so far such neoadjuvant chemotherapy does not
compromise later radical radiotherapy. To date we have not
documented progression of local disease during the
chemotherapy phase of this combined treatment.
A comparison of remote afterloaded and manually inserted
caesium in the treatment of carcinoma of the cervix
R.D. Jones, R.P. Symonds, J. Laurie, T. Habeshaw,
E.R. Watson & D.A. Lamont
Beatson Oncology Centre and West ofScotland Cancer
Surveillance Unit, Glasgow, UK.
Between 1982 and 1985, 240 patients with carcinoma of the
cervix were treated with radical radiotherapy. One hundred
and forty were treated with the selection as the intracavity
component of their therapy, and 100 received conventional
caesium.
To allow for the increased dose rate to point A with the
selectron (1.2-1.4 Gy h') compared with caesium
(0.55 Gy h-') a correction taking account of the cumulative
radiation effect (CRE) formula was applied.
The overall 2-year disease free survival was comparable in
the two groups (68.6% selectron vs 73% caesium) but in
stage II patients the local control rate in the selectron group
tended to be poorer (67.4% vs 85.7%, P <0.10). This
difference may at least in part be due to the bulkier tumours
in the selectron stage II group. There appeared to be no
increase in late complications in patients treated by selectron
(12.9%) compared with conventionally treated patients
(15%).
The introduction of the selectron has brought about a
marked reduction in staff radiation exposure. In the Royal
Beatson Memorial Hospital the annual radiation exposure of
nursing staff fell from 19 mSv in 1981 to 2.4mSv in 1985.
Young age as a prognostic factor in cervical cancer
R. Kalra, E. Sugden & C.J. Alcock
Department ofRadiotherapy and Oncology, Churchill
Hospital, Oxford, UK.
The importance of young age as an independent prognostic
factor remains uncertain. Retrospective analysis of 1,027
patients referred to the Department of Radiotherapy and
Oncology in Oxford between January 1970 and December
1987 has shown an increase in the annual total of patients
from 42 to 69 in this period. This is principally due to an
increase in the number of patients under 40 years of age.
Younger patients presented with earlier disease (FIGO stage
I and II age <40: 93%, age >40: 72%). The proportion of
adenocarcinoma was 17% for age <40 and 13% for age
> 40. There was no real difference in the incidence of pelvic
node metastases at Wertheim's hysterectomy between the two
age groups over the period studied. These results and an
analysis of survival will be discussed further.
Mortality in patients with testicular cancer: review of results of
treatment
R.T.D. Oliver, M.V. Williams, M.J. Ostrowski, W. Jackson
& H. Baillie-Johnson
London, Addenbrookes and Norfolk and Norwich Hospitals,
UK.
The previous review of results from East Anglian region
treated between 1980 and 1984 reported 10.8% mortality,
only 70% of which were due to progressive disease. In an
attempt to improve on these results, The Anglian Germ
Tumour Group agreed to standardise treatment with surveil-
lance for stage I seminoma, and malignant teratoma and
three day etoposide prolonged infusion bleomycin and cis-
platin (EBCi (3)) for all patients with metastases, although
one centre continued to pilot a phase 2 study of single agent
cisplatin in patients with metastatic seminoma. Three hun-
dred and twenty-eight patients have been reviewed and cur-
rently 93% are alive and disease-free, including 85% of 105
with metastatic malignant teratoma (61% of 23 patients con-
sidered very advanced by MRC criteria); 90% of 50 patients
with metastatic seminoma; and 98% of 162 patients with
stage I tumours (100 teratoma, 64 seminoma). Multivariate
analysis demonstrated hCG level and extent of lung meta-
stases, are the most important prognostic factors for drug
resistance in patients with metastases and malignant teratoma
undifferentiated had the highest frequency of relapse on
surveillance (MTU 56%, MTI 68%, seminoma 76% con-
tinuously disease-free at 5 years).180 BRITISH ONCOLOGICAL SOCIETY MEETING
Prediction ofoutcome in ovarian cancer using tumour activity
indices
C.W.E. Redman, D.M. Luesley, K. Ward, E.J. Buxton &
K. Kelly
University Dept ofObstetrics and Gynacology and CRC West
Midlands Clinical Trials Unit, Birmingham, UK.
The management of EOC is largely consequent on FIGO
stage and the presence or absence of residual disease after
primary surgery, which are important prognostic factors but
indirect indices of tumour biology. Direct assessment of
tumour cell activity may enhance prediction of outcome, but
conventional parameters, such tumour differentiation are
subject to considerable observer error and limited by tumour
heterogenicity. Flow cytometry has enabled the objective
assessment of cellular morphology and activity, which can
also be biochemically evaluated by measuring products of
cellular metabolism, such as cyclic 3'5' guanosine monophos-
phate (cGMP). Using paraffin-embedded formalin-fixed
material obtained from the primary operation, an analysis of
the correlation between nuclear ploidy and the proliferative
index (PI) as quantified by flow cytometry with random
pre-treatment urinary cGMP was performed in 40 EOC
patients. The majority of the study group had advanced
disease (28 FIGO III/IV) and residual disease (31). All but
three (stage I) patients received single agent high dose cis-
platinum as first-line therapy (100 mg m-2 x 5); in patients
with evaluable disease there was a response rate of 64%.
Thirty three patients have died; the median survival of the
study population being 17 months. There was a significant
correlation between cGMP and PI. Significantly more aneu-
ploud tumours had elevated PI values (X21 = 0.007). No prog-
nostic variable independently predicted for response. An
initial univariate log rank analysis analysis identified stage,
the amount of residual disease, histological type, and PI as
prognostic factors but because of the interrelation between
these and other factors, and as a number of factors did not
conform to the proportional hazards model, a multivariate
stepwise discriminant analysis was performed using survival
at 46 months (the minimum follow-up for surviving patients)
as the end point. On the basis of this cGMP was the most
prognostically important proliferative activity factor, which
in conjunction with residual disease status can correctly
predict outcome in 80% of cases.
Smear cytology post-radiotherapy for squamous cell carcinoma
cervix. A worthwhile test?
S.J. Whitaker, P.R. Blake & P.A. Trott
Royal Marsden Hospital, London, UK.
Radical radiotherapy can induce changes in exfoliated
epithelium which makes the diagnosis of recurrent disease by
cytology difficult. We present a review of our routine screen-
ing policy at the Royal Marsden Hospital (RMH), to
evaluate its place in the early detection of persistent and
recurrent disease.
From hospital and cytology records from 1975 to 1988 we
identified 22 cases of recurrent squamous carcinoma cervix
post-RI. Eleven were recurrent at initial presentation. All had
received radical RT. Their initial stages were: Ib, six cases;
Ila, four; Ilb, five and IlIb, four cases. We also reviewed the
results of all follow-up smears from 1987 and 1988 and their
clinicopathological correlation.
The median time to diagnosis of persistent and recurrent
disease overall was 8 months (2-50). This was shorter for
more advanced FIGO stages, 21 months for stage Ib, 18.5
months for Ila, 9.5 months for IIb and 2.7 months for stage
IIIb. The features of their smears are presented. Of smears in
1987, 140/170 (89%) were normal, and in 1988, 160/212
(81%) were normal examinations. Two of five smears
reported C4 or 5 in 1987 were false positive and 0/6 in 1988,
giving a specificity of 60% and 100% respectively. Twelve
patients had normal smears but abnormal clinical findings in
1987. Three had recurrence confirmed giving a false negative
rate of 3/152. There were no proven recurrences with normal
smears in 1988, giving a sensitivity of 98% and 100% for
1987 and 1988. In addition we identified three subclinical,
operable recurrences by cytology, proven at subsequent EUA
and biopsy.
Routine screening cytology is a useful and reliable adjunct
to regular pelvix examinations for follow-up of irradiated
squamous carcinoma cervix.
Evaluation of a semi-automated tetrazolium assay in
chemosensitivity testing ofovarian malignancy
J.K. Wilson, J.M. Sargent, A.W. Elgie, C.G. Taylor &
J.G. Hill
Pembury Hospital, Tunbridge Wells, UK.
We describe a feasibility study using Mosmann's 3-(4,5-
dimethylthiazol-2-yl)-2,5 diphenyltetrazolium bromide (MTT)
assay for assessing the chemosensitivity of primary ovarian
tumour samples to cytotoxic drugs. Ascitic fluid and/or
tumour biopsy samples have been collected by paracentesis
or at laparotomy from patients with ovarian malignancy.
Single cell suspensions were prepared and the viability and
morphology assessed. The cells were continuously exposed to
cytotoxic drugs for 48 h in microtitre plates. The MTT assay,
which assesses mitochondrial activity, was used to determine
the number of living cells remaining. To validate the assay
we have demonstrated the linear relationship between cell
numbers and the optical densitiy of the formazan they pro-
duce from the tetrazolium salt. Cell survival after drug
exposure was expressed as a percentage of control cells.
Dose-response curves for each drug were obtained. We
found the drug effects varied considerably between each sam-
ple tested. Cells obtained from ascitic fluid and solid tumour
in the same patient showed very similar drug effects.
In view of the disappointing results of clonogenic assays in
this type of tumour, we believe this simple, rapid, semi-
automated, non-clonogenic assay may offer a better oppor-
tunity for chemosensitivity testing in ovarian malignancy,
with the possibility of selecting agents for each individual.
Radiotherapy
Dosimetry of neck irra,diation
R.A. Eeles, M. Chow, W.P.M. Mayles & J.M. Henk
Royal Marsden Hospital, Sutton, Surrey, UK.
When treating cancer of the head and neck, irradiation of the
neck is often given using a single anterior field with a central
block, 2 cm wide, to shield the spinal cord and larynx. The
aim of this study was to look at the doses received by the
different lymph node groups in the neck, the effect of the
central block, and the dose distribution at the match line of
an anterior neck field and a lateral field, such as that used in
treating nasopharyngeal carcinoma.
Five patients, with different sized necks, were CT scanned
in the treatment position. The position of the various neck
node groups, i.e. the anterior cervical chain including the
scalene nodes, the posterior chain, and the retropharyngeal
nodes, were marked on each CT slice. Plans were done at
1 cm intervals using the TARGET and experimental
JCPLAN systems. Doses to nodes in the posterior cervical
chain were between 70 and 80% of the applied dose when the
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combinations give a better distribution: either a single
anterior 10 MV or a mixture of 60 MV and 25 MV anterior
beams, or the addition of a posterior field to the 6 MV
anterior field.
Scalene nodes at the inferior end of the anterior cervical
chain may be shielded by the central block if it is 2 cm wide
throughout its length.
These findings may be important when treating cancers of
the head and neck where there is a high incidence of metas-
tatic disease in the posterior cervical nodes, such as
nasopharyngeal carcinoma.
The effect of radiotherapy for squamous carcinoma of head
and neck mucosa on parotid salivary composition
M.N. Gaze, J.R. Barton & M. Riad
Departments ofClinical Oncology, Medicine and
Otolaryngology, University ofEdinburgh, Western General
Hospital and Royal Infirmary, Edinburgh, UK.
To investigate the effects of malignancy, radiotherapy and
smoking on mucosal immunity, the flow rate and immuno-
globulin (Ig) profile of pure parotid saliva were measured in
both healthy controls and patients with squamous carcinoma
of head and neck mucosa. The controls were either smokers
(47) or non-smokers (30). The patients were either untreated
(30) or previously irradiated (30). In addition paired samples
were obtained from 14 patients prior to and on completion
of radical radiotherapy.
It was found that smoking significantly decreased salivary
IgA and increased IgM (P < l0-5). This effect was related to
the number of cigarettes smoked (P < 10-5), and reversed in
former smokers. Similarly salivary IgA was significantly
decreased, and IgM increased in cancer patients compared
with controls, but this finding did not change with treatment,
although flow rate increased with radiotherapy.
The observed changes in cancer patients may simply reflect
the fact that most were smokers. The possibility that
smoking-induced mucosal immunodeficiency may be an
important aetiological factor in upper aerodigestive tract
cancer merits further investigation.
The recording of morbidity due to radiotherapy
E. Lartigau, S. Dische & M. Warburton
Marie Curie Research Wing, Mount Vernon Hospital,
Northwood, UK.
In the trial of methods to improve radiotherapy, morbidity
(early and late) must be monitored with the same care as
tumour control. Although there are universally agreed
systems for the staging of tumours, the recording of radiation
dose and the expression of tumour response, there is still no
generally employed scheme for the measurement and record-
ing of radiation morbidity. Morbidity consists of symptoms,
complications, investigations and treatment. It is possible to
abstract these elements and to record them individually. A
dictionary of recording of radiation morbidity has been
developed in this centre and a fourth draft is available. It is
divided into 34 sites, from adrenal gland to vagina and
cervix. For each site a list of basic and optional items has
been prepared. For a treated area, more than one of the site
lists is, in general, required; however, it may be decided that
only a few items in each list should be used. Finally, from
these elements a simple computer program can grade the
severity using any previously established grading system or
any new one which may be devised. We have used this
dictionary prospectively since 1986 for the recording of early
and late reactions in patients treated by our accelerated
hyperfractionated regimen (CHART). For 196 patients
treated so far we have used the system at each follow-up
clinic with a high level of agreement between observers.
Result of the regimen can be given according to any early or
late side-effect. We are now doing a retrospective clinical
study comparing three groups of 20 patients previously
treated by CHART, conventional or hypofractionated
radiotherapy for ENT carcinoma. This study will permit us
to assess the sensitivity of the system by comparing different
treatment methods with different expected morbidity. After
the current final revision in consultation with up to 90 cen-
tres worldwide, we expect that such a system for recording
morbidity will be internationally agreed and accepted.
BNLI results of initial treatment using radiotherapy in the
treatment of non-Hodgkin's lymphoma of the palatine tonsil
C.H. Macmillan, G. Vaughan Hudson, M.H. Bennett,
B. Vaughan Hudson & A.R. Makepeace
British National Lymphoma Investigation, University College
and Middlesex School ofMedicine, London, UK.
Between 1974 and 1988, 56 patients with stage IE (n = 24)
and IIE (n = 32) non-Hodgkin's lymphoma (NHL) of the
palatine tonsil registered with the British National Lym-
phoma Investigation (BNLI) were treated primarily with
radiotherapy alone.
The sex ratio was equal. Mean age overall was 59 (range
25-89). Overall CR rate at 3 months post-treatment was
75% (42/56) (stage IE 83% (20/24), IIE 72% (23/32)). Thir-
teen patients failed to enter CR; two failed within the radia-
tion field, one 'in-field' and generalised, two in an adjacent
site, five intra-abdominally, one in the groin, one at un-
specified site, and one died of CVA at 2 months. Fourteen
patients relapsed after achieving CR, sites of relapse were:
intra-abdominal (7), adjacent (2), 'in-field' (1), bone (2), CNS
(1) and groin (1). Only four patients were either not con-
trolled locally by RT or experienced first relapse in the
irradiated area.
Twenty-three patients have died. In 16 instances (70%),
death was either due to NHL or the patient had active
disease when last seen.
There was a significant correlation between survival and
age at presentation, with younger patients faring better. A
significant difference in disease-free survival existed between
stages I and II in favour of stage I, but there was no
significant difference in survival overall.
A feasibility study of twice daily continuous fractionated
radiotherapy in a range of malignant tumours
M. Moriatry, M. Pomeroy, M. Maher & I. Fraser
Saint Luke's Hospital, Dublin 6, Ireland.
In 1987 Saunders and Dische presented preliminary results of
a continuous hyperfractionated radiotherapy (CHART)
regime used at two sites. The results were exciting and are
being investigated further. Their schema involved a three
times daily regime. A twice daily schema is more practical in
our centre and the objectives of the study are to test the
feasibility and toxicity of a twice daily continuous hyperfrac-
tionated schema and also to explore the possibilities of intro-
ducing chemotherapy in sequence with this radiotherapy
regime.
It is aimed to treat up to 60 patients in this study by July
1989. So far 23 patients have been treated: (four) H and N,
eight breast carcinoma, five lung carcinoma, four brain
glioma (III or IV) and two recurrent pe,vic lesions. In general
volumes are kept as small as possible and doses used are TD
of 5,000-5,250 rad, 30 treatments, 15 days (>6 h between
fractions). Chemotherapy in conjunction has not been used
yet.
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for brain, breast and lung tissue. The acute reaction for two
of the head and neck cases has been judged to be severe
(grade III and IV) and to last for up to one month post
treatment. Small bowel tolerance was a problem in one ofthe
two cases of pelvic R/T and treatment was stopped at
4,000 rad TD. The study is ongoing with the introduction of
sequenced chemotherapy into the brain, lung and breast
cases now.
Radiobiological comparisons between low dose-rate and
fractionated TBI
J.A. O'Donoghue
Radiation Oncology Research Group, Beatson Oncology
Centre, Belvidere Hospital, London Road, Glasgow, UK.
The LQ model was used to compare fractionated TBI with
single doses given at a low dose-rate (LDR). Fractionated
and LDR treatments of the same total dose (i.e. same
antileukaemic effect) may also produce equal lung damage.
The table shows two fractionated TBI schedules and the
predicted irradiation times for equivalent LDR treatments.
These times depend on lung repair kinetics and results for
three different half-times are shown. The irradiation times for
LDR treatments appear to be impractically long.
Fractionated LDR treatments were also examined. Taking
an a/P ratio of 3 Gy and a repair half-time of 1.5 h for lung
the irradiation times predicted to enable a specified dose
increase are shown in the second table. There appears to be
little to be gained by this approach.
Repair half-time (h) 6 x 2 Gy 10 x 1.4 Gy
1.0 16h 27h
1.5 24h 41 h
2.0 31 h 55h
Fraction size 5% 10% 15%
2.0Gy 1.lh 2.3h 3.5h
1.4Gy 1,4h 2.9h 4.7h
Double half body irradiation for drug-resistant multiple
myeloma: an effective and well tolerated salvage regimen
J.S. Tobias, F.J. Giles, C.R.J. Singer, J.D.M. Richards &
A.H. Goldstone
Depts of Radiotherapy, Oncology and Haematology,
University College Hospital, London WCJ, UK.
Out of a total of 89 patients treated with single or double
hemibody irradiation for drug resistant myeloma, 42 have
received both upper and lower halves (DHBI). All had
disease progression despite standard regimens of melphalan/
prednisone (median eight courses, range 4-24); seven had
primary chemoresistance. Four had also been treated with
VAD, three with ABCM. Fifteen had previously undergone
localised radiotherapy. Evidence for drug resistance: rising
immunoglobulin (27 pts), pain (33), hypercalcaemia (7), in-
creasing proteinuria (7). Fourteen had severe lytic bone
lesions. Using standard MRC criteria, six pts were stage 1, 22
stage 2 and 14 stage 3. Treatment consisted of single-fraction
upper HBI to 7.5 Gy using anteroposterior fields on ' Co at
SSD 200 ± 12cm, dose rate 0.2-2.25 Gy min-', treatment
time 40-60 min. After min 5 weeks we treated the lower half
to total 10 Gy (single fraction with dose rate and position as
before). Treatment was well tolerated with no treatment
deaths though three pts died within 3 months from disease.
Platelet transfusion (Tx) was needed in seven pts (mean
period 3 weeks) and red cell Tx in 40, after the second HBI
(usually a single Tx). Response included symptomatic benefit
(30/33 pts with pain relief, many discontinuing opiates); 22/
27 >25% fall in M-band; four reversal of Bence Jones
proteinuria, six hypercalcaemia. Mean survival is 12 mth; 19
are alive, six at > 2 years without further treatment. Cur-
rently, patients are randomised after DHBI to receive sub-
cutaneous cc-interferon as maintenance (Intron, Kirkby-
Warrick, 3 MU 3 times a week) or no further treatment.
Radiotherapy for cholangiocarcinoma: the Hammersmith
Hospital experience
K.A. Vallis, H.R. Gompertz, I.S. Benjamin & A.J. Munro
Department ofClinical Oncology, Hammersmith Hospital,
UK.
Cholangiocarcinomas are rare tumours which, because of
their anatomical location, are only occasionally curable by
surgery alone. They tend to be slowly growing tumours and
some encouraging results have been reported with
radiotherapy. Between August 1986 and January 1989, 29
patients with cholangiocarcinoma were referred from the
Hepatobiliary Unit at the Hammersmith Hospital for a
radiotherapy opinion. The mean age of these patients was
55.4 years with a range of 22-79 years. The male to female
ratio was 2.6:1.
Of these 29 patients, eight had undergone either radical
excision of tumour or palliative bypass procedure. In the
remainder biliary stents were inserted to relieve obstructive
jaundice. Nine patients were considered to be in such poor
condition that radiotherapy was not indicated. The
radiotherapy regimes used were as follows: external beam
therapy alone (six patients); external beam therapy combined
with interstitial therapy (eight patients); and interstitial
therapy alone (six patients). Brachytherapy was given in the
form of iridium-192 wire inserted via a percutaneous trans-
hepatic catheter.
Of the 20 patients treated by radiotherapy, follow-up data
are available for 19. Ten patients have died, with a mean
survival of 9 months after radiotherapy. Nine patients are
alive with a mean follow up of 10 months.
The technique of intracavitary treatment for cholangiocar-
cinoma will be described and the data on this series of 29
patients presented.
The relation of tumour curability to tumour size for
biologically targeted radiotherapy
T.E. Wheldon, J.A. O'Donoghue & A. Barrett
Beatson Oncology Centre, Belvidere Hospital, Glasgow and
Department ofClinical Physics, University ofGlasgow, UK.
In conventional radiotherapy, smaller tumours are invariably
more radiocurable than larger ones. In targeted radiotherapy,
the lesser cell content of smaller tumours may be offset by
reduced efficiency of absorption of radioactive disintegration
energy from radionuclides which are long range P-emitters.
We have used a mathematical model based on Poisson statis-
tics to evaluate relative curability of tumours with cell con-
tent from 10' to 10'0 cells using targeted '"'I or 90Y. The
analysis made use of available microdosimetric data on
energy absorption by very small spheres. Computer simula-
tions were carried out for a wide range of therapeutic
radionuclide activities (e.g. 0-1000 mCi '3'I) for varying
specific uptake of activity by tumour cells (e.g.
0.00001-0.001 g-') and differing clonogenic fraction (e.g.
0.05-0.5). The results show that, for each radionuclide, there
is a tumour size region within which tumour radiocurability
is maximum. For '"II, the optimal cure region is close to
approximately 106 cell content, while for 9Y it is close to
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curability decreases due to increasing cell number. Below this
cell content, curability decreases due to reduced efficiency of
energy absorption. Targeted radiotherapy with '3'I or 90Y
differs from conventional radiotherapy in that microscopic
tumours may be less easily cured than small macroscopic
ones. Computer simulation studies suggest that a combina-
tion regime with both targeted and conventional
radiotherapy may be the optimal strategy for treatment of
patients with disseminated disease consisting of tumours and
micrometastases of differing size.
Central nervous system, lung, and head and
neck cancer
Long-term survival in gliomas: prognostic factors and quality
of outcome
S. Awwad, A. Cull & A. Gregor
Department of Clinical Oncology, Western General Hospital,
Edinburgh, UK.
One hundred and eleven patients with previously untreated
gliomas were referred to the Department of Clinical
Oncology in Edinburgh between 1983 and 1985. There were
79 males, 32 females and 11 children (<15 years); 22 were
15-45 years; 28 were 46-55 years and 49 patients were older
than 55 years at presentation. One hundred and one patients
had hemispheric tumours. Histological confirmation was
obtained in 87 (78.4%). Sixty-seven were classified as astro-
cytomas. Surgical removal was attempted in 61 patients
(complete in 22 and partial 39). Twenty-nine patients were
biopsied and in 21 diagnosis was not histologically
confirmed. One hundred and three patients underwent radical
radiotherapy. Fifty-two mixed beam of photons (2,O4OcGy in
12 fractions over 4 weeks) and neutrons (600cGy in 12
fractions over 4 weeks). Fifty-one patients received pure
photon beam 4,736 cGy average central dose in 20 fractions
over 4 weeks. Whole brain irradiation was used in all but 12
patients (11 children). Minimal follow-up of 3 years is
available on all patients. Five year actuarial survival is 6.2%
for the whole population and 4.7% if children are excluded.
Prognostic factors significantly influencing survival are age at
diagnosis (P = 0.007), histological grade of astrocytoma,
grade I + II = 15%, III = 4%, IV = 0% (P = 0.005). Dura-
tion of symptoms, extent of surgical resection and photon
radiotherapy show a trend in improved survival. Detailed
assessment of survivors including neuro functional,
psychometric, hormonal and radiological assessment is in
progress and will be presented. Significant proportion of long
term survivors show late morbidity seriously effecting their
quality of life.
The influence of MRI on the treatment of spinal cord
compression
J.D. Graham, P.J. Hoskin & M. Williams
Royal Marsden Hospital, Sutton, UK.
In the treatment of spinal cord compression by radiotherapy,
conventionally a 5 cm margin (or two vertebral bodies) is
given above and below the site of compression. In the diag-
nosis of spinal cord compression the introduction of
magnetic resonance imaging (MRI) has significantly im-
proved the quality of diagnostic images compared to myelo-
graphy. No study has investigated the influence of MRI on
clinical decision making in spinal cord compression.
Eleven cases have been reviewed in which both myelo-
graphy and MRI were performed prior to treatment. Taking
account of clinical findings, the results of each diagnostic
technique were independently reviewed and an appropriate
radiotherapy volume proposed. The field lengths based on
MRI were significantly less than those based on myelography
(P <0.02). However, the actual field sizes used did not
reflect the additional information from MRI. In only one
case did MRI add information which significantly altered the
radiation field. Myelography remains an accurate method of
diagnosis for the majority of patients and this study suggests
that smaller margins above and below the radiographic site
of compression may be used. It is recommended that a 2 cm
or one vertebral body margin should be adequate.
The influence ofsite and local management on the outcome of
radiotherapy for cerebral metastases
P.J. Hoskin, J. Crow & H.T. Ford
Royal Marsden Hospital, Sutton, Surrey, UK.
A retrospective analysis of 164 patients treated with
radiotherapy for cerebral metastases between January 1978
and January 1988 will be presented. These patients reflect a
policy of whole brain irradiation, delivering a mid-plane dose
of 35 Gy in 15 daily fractions. In selected patients having a
solitary localised site of metastasis and stable or absent
disease elsewhere a boost of 15 Gy in eight daily fractions
was given. These patients had predominantly primary
tumours of lung (52%) or breast (29%); other primary sites
included melanoma (8%), kidney (3%), bladder (2%) and
colon (2%). The diagnosis of cerebral metastases was
confirmed by CT scan in 144 (88%) patients, and by isotope
scan in the remainder.
Oral dexamethasone was given to all but 11 patients. One
hundred and fourteen (69.5%) received whole brain irradia-
tion alone and 50 (30%) received the additional boost.
Median survival (range) in patients receiving no boost was
116 days (13-1,436) compared to 140 days (32-974) in those
receiving a boost. Progressive cerebral metastases were a
cause of death in 43 (26%) of all patients, 13 of whom
received a boost. Despite the selection criteria for receiving a
boost, 30 (60%) of those who did so died with progressive
distant metastases outside the brain, 10 (20%) died with
progressive primary tumour.
Combination chemotherapy (C/T) with mitomycin, ifosfamide
and cisplatin in advanced non-small cell lung cancer
D.W. Miles, H.M. Earl, J. Drake, D.C. Currie, S.G. Spiro,
R.L. Souhami, P.G. Harper & J.S. Tobias
Guy's Hospital, University College Hospital, andBrompton
Hospital, London, UK.
Mitomycin C (M), ifosfamide (I) and cisplatin (C) are among
the most active single agents in non-small cell lung cancer
(NSCLC). A recent report (Cullen et al. (1988) Br. J. Cancer,
58, 359) showed an overall response rate of 56% in 74
patients (67% LD, 35% ED). We report a further study to
confirm these findings. Forty-five patients (six previously
treated with surgery ± R/T or C/T ± R/T) were treated with
M 6 mg m-2, I 3 g m-2 (with MESNA protection) and C
50 mgm2, every 21 days. Patients were reassessed after two
courses ofC/T and, if responsive, treatment was continued to
four course in 18 cases and up to six courses in four cases.
There were 45 pts: ECOG 0-2, 34 M, 11 F, 18 limited
disease (LD), 27 extensive disease (ED), median age 57,
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All pts n (%) Squamous Adeno Large cell LD ED
No pts 45 23 10 12 18 27
OR 18 (40%) 11 (48%) 2 (20%) 5 (42%) 8 (44%) 10 (37%)
CR 4 (9%) 1 (10%) 1 (10%) 2 (17%) 2 (11%) 2 (7%)
PR 14 (31%) 10 (44%) 1 (10%) 3 (25%) 6 (33%) 8 (30%)
Median survival = 36 weeks (LD 41 weeks, ED 25 weeks).
The major toxicity was gastrointestinal (GI) of 42 pts
assessible for GI toxicity, 13 experienced WHO grade III
nausea and vomiting, one patient had intractable (grade IV)
vomiting. All pts developed alopecia. There was no
significant nephrotoxicity. On five occasions pretreatment
WBC was less than 3.0 x I091-' and treatment was delayed.
These results confirm that MIC is an active regimen in
NSCLC, but the results in LD are not equal to those of
Cullen et al.
Chemotherapy or total body irradiation for limited or extensive
small cell carcinoma of the bronchus
G.A. Newaishy
Clinical Oncology Department, Edinburgh, UK.
A controlled trial of localised radiotherapy in combination
with either chemotherapy or total body irradiation (TBI) was
planned for patients with small cell carcinoma of the bron-
chus. The trial continued non-controlled due to the low
intake. Systemic treatment was to be given as adjuvant or at
recurrence. The TBI using small fractionated doses (150 cGy
in 15 fractions) was ineffective and was discontinued, and
was not given at recurrence. Thirty-one patients received
adjuvant chemotherapy and 13 had adjuvant TBI. Their
1 year survival rates (SR) were 29% and 15.4% respectively.
All patients who received TBI were dead within 20 months,
while 9.7% of those who received chemotherapy were alive at
5 years. The median survival (MS) of the 31 patients was
32 weeks and that of the 13 patients was 33.8 weeks. Seven-
teen other patients received chemotherapy at the time of
recurrence. Their 1 and 5 year SR were 70.6% and 0%
respectively (MS 77 weeks). Analysis was made of patients
who received chemotherapy according to the stage of disease.
Seventeen of 29 patients with limited disease received
adjuvant chemotherapy and 12 patients received delayed
chemotherapy. Five (29.4%) and three (17.6) of the 17
patients lived for 1 and 5 years respectively. Ten (83.3%) and
two (16.6%) of the 12 patients lived for 1 and 4 years but
were dead by 5 years. The MS of these two groups of
patients were 29weeks and 81 weeks respectively. Fourteen
of the 19 patients who had extensive disease had adjuvant
chemotherapy and five patients received delayed chemo-
therapy. Four of the 14 patients (28.6%) and two (40%) of
the five patients lived for 1 year. All the 14 patients died by
16 months and the five patients died by 25 months. The MS
of these two groups of patients was 37 and 42.2 weeks
respectively.
Non-small cell lung cancer: how the experts want to be treated
M.J. Palmer & W.J. Mackillop
Kingston Regional Cancer Centre, Kingston, Canada.
Four hundred and sixty one doctors who treat lung cancer in
the USA and Canada responded to a mail questionnaire that
asked how they would wish to be managed if they developed
non-small cell lung cancer (NSCLC). There was no consensus
as to preferred treatment in either of two clinical situations
described. Most doctors (74%) wanted radiotherapy as a
part of their management for NSCLC with extensive node
involvement, but 28.5% wanted chemotherapy, 21.5%
wanted surgery and 17% wanted no active treatment.
American and Canadian doctors had different treatment
preferences (P <0.005). Radiation therapy, chemotherapy
and surgery were most frequently favoured by radiation
therapists, medical oncologists and thoracic surgeons, respec-
tively (P <0.025). Most doctors (81%) wanted radiotherapy
to the painful area if they had NSCLC with bone metastases,
while 28% wanted chemotherapy and 21% wanted
radiotherapy to the primary lesion as part of their manage-
ment. Forty-five per cent of American doctors would want
treatment involving chemotherapy compared to 6% of
Canadian doctors (P <0.001). Chemotherapy was favoured
by 49% of medical oncologists compared to 6% of radiation
therapists (P <0.001), whereas 12% of medical oncologists
wanted radiotherapy to their chest compared to 40% of
radiation therapists (P <0.001). Almost all of the doctors
would recommend for their patients the treatment that they
chose for themselves. It was concluded that physician bias is
an important factor in determining how patients with
NSCLC are treated. Doctors were also asked if they would
participate in three clinical trials if they developed NSCLC.
Only 22-46% of the doctors were willing to consent to each
of the trials, but almost twice as many were willing to ask
their patients to participate.
The management of tumours arising in the maxillary antrum
G.S. Rao, A.G. Robertson, D.S. Soutar & A. Al-Sammarie
Canniesburn Hospital, Bearsden, The Institute of
Radiotherapy, Kuwait, and Beatson Oncology Centre,
Glasgow.
Eighty-eight cases of tumours arising in the maxillary antrum
underwent treatment between 1967 and 1989. The series com-
prised 34 females and 54 males, with ages ranging from 9 to
93 years and an average of 63 years.
Follow-up varied from 6 months to 14 years with a
minimum follow-up of 6 months.
Sixty-two patients had squamous cell carcinomas, the
remaining various histologies including adenoid cystic car-
cinoma, sarcoma and lymphoma. All patients were staged
retrospectively (UICC, 1984). Sixty-two cases of squamous
cell carcinoma were treated either by XRT (41) or surgery
and post-operative XRT as a combined modality treatment
(2). Nodal involvement at the time of presentation occurred
in 6 cases and was associated with a poor prognosis, all
patients dying of tumour within 3-66 months following
treatment.
Early tumours (T2 NO) were adequately controlled by
radical radiotherapy alone with a 5-year survival of 69%. In
more advanced tumours (T3 NO and T4 NO) radical radio-
therapy alone was less successful with the 5-year survival
falling to 19%. Combined modality treatment comprising
radical surgery followed by radical post-operative
radiotherapy improved 5-year survival in advanced tumours
to 61%.
Parotidectomy for malignant salivary tumours and for
metastatic melanoma in pre-auricular lymph nodes
A.B.S. Ball & J. Meirion Thomas
Westminster and Royal Marsden Hospital, London, UK.
Formal parotidectomy was performed in 120 patients by one
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salivary tumours, of which eight were recurrent. The policy
was to treat all untreated high-grade tumours (HGT) by
preoperative radiotherapy. Low-grade tumours (LGT) (some
muco-epidermoid, all adenoid cystic and acinic cell car-
cinomas) were treated by surgery alone. In both groups the
purpose of surgery was to achieve tumour clearance while
preserving the stem and any branches of the facial nerve not
already destroyed. Of 10 patients with HGT, six had com-
plete facial palsy at presentation due to tumour. Of eight
patients with LGT, two had partial facial palsy due to
previous surgery. Following surgery only one patient suffered
further permanent deterioration of facial nerve function. The
decision to perform radical neck dissection (RND) was taken
at the time of surgery by biopsy and frozen section of the
jugulo-digastric node which was positive in five patients, only
one of whom had palpable matastatic cervical lymph-
adenopathy. Five patients have died from metastases 8-47
months from initial presentation, and one has local recur-
rence after surgery: all had HGT.
Eight patients with malignant melanoma presented with
pre-auricular node metastases. Diagnosis was confirmed by
cytology and each patient was treated by superficial
parotidectomy and RND. Cervical nodes were positive in six.
Four patients have died of metastatic disease and one has
local recurrence. Effective regional node dissection for pallia-
tion of melanoma is recommended.
investigation of choice in patients with suspected spinal cord
compression (SCC). Between September 1987 and July 1988
MRI demonstrated distortion of the spinal cord due to
metastatic malignancy in 29 patients presenting with clinical
features of SCC. The cord was compressed by bone in four
and by soft tissue in 25 patients. Nineteen patients had an
anterior, 10 a posterior, seven a lateral and five more than
one component to the direction of compression. The length
of lesion was 1- 12 cm and was 3 cm or larger in seven
patients.
We were not able to demonstrate a significant correlation
between the anatomical details obtained from MRI images
(direction, length and the anatomical level of compression)
and the presenting clinical features (the type of neurological
deficit and the degree of motor impairment).
Planned course of radiotherapy was completed as the sole
mode of treatment in 23 patients. Nine improved
neurologically. The pre-treatment MRI images did not
predict the results of therapy.
The additional information obtained from MRI allows for
more accurate delivery of radiotherapy, but the anatomical
detail does not correlate with functional deficit and the out-
come of treatment.
Spinal cord compression due to metastatic malignancy:
comparison of clinical features and magnetic resonance (MRI)
images
D.J. Grant, M.P. Williams, D.W.O. Tilsley & M. Brada
Academic Radiotherapy Unit and Department ofDiagnostic
Radiology, Royal Marsden Hospital, Sutton, UK.
MRI enables the spinal cord and surrounding structures to
be visualised in a non-invasive manner and has become the